# EDGAR Filing Document

**Accession Number:** 0000072331
**File Stem:** 0000072331-23-000045
**Filing Date:** 2023-2
**Character Count:** 180081
**Document Hash:** 14d664c4542f7528d25c3b286c159cfb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000072331-23-000045.hdr.sgml**: 20230223

**ACCESSION NUMBER**: 0000072331-23-000045

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 88

**CONFORMED PERIOD OF REPORT**: 20230131

**FILED AS OF DATE**: 20230223

**DATE AS OF CHANGE**: 20230223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NORDSON CORP
- **CENTRAL INDEX KEY:** 0000072331
- **STANDARD INDUSTRIAL CLASSIFICATION:** GENERAL INDUSTRIAL MACHINERY & EQUIPMENT, NEC [3569]
- **IRS NUMBER:** 340590250
- **STATE OF INCORPORATION:** OH
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-07977
- **FILM NUMBER:** 23658463

**BUSINESS ADDRESS:**
- **STREET 1:** 28601 CLEMENS RD
- **CITY:** WESTLAKE
- **STATE:** OH
- **ZIP:** 44145
- **BUSINESS PHONE:** 4408921580

**MAIL ADDRESS:**
- **STREET 1:** 28601 CLEMENS ROAD
- **CITY:** WESTLAKE
- **STATE:** OH
- **ZIP:** 44145

?xml version="1.0" ? ndsn-20230131

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

**(Mark One)**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended January 31, 2023** 

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> to <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>**

**Commission file number 0-7977**

**____________________________________________________**

**NORDSON CORPORATION**

**(Exact name of registrant as specified in its charter)**

**___________________________________________________**

**Ohio**

**(State or other jurisdiction of incorporation or organization)**

**28601 Clemens Road**

**Westlake, Ohio**

**(Address of principal executive offices)**

**34-0590250**

**(I.R.S. Employer Identification No.)**

**44145**

**(Zip Code)**

**(440) 892-1580**

**(Registrant's Telephone Number, Including Area Code)**

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of Each Exchange<br>On Which Registered** |
| Common Shares, without par value | NDSN | Nasdaq Stock Market LLC |

---

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes ⌧&nbsp;&nbsp;&nbsp;&nbsp;No □

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes ⌧&nbsp;&nbsp;&nbsp;&nbsp;No □

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| Emerging growth company | ☐ | | |

---

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;No ⌧

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: Common Shares, without par value as of February 21, 2023: 57,260,973

------

**Table of Contents**

---

| | |
|:---|:---|
| <u>[PART I – FINANCIAL INFORMATION](#idc5fa716a67d404f960e08e66d495bbb_10)</u> | [3](#idc5fa716a67d404f960e08e66d495bbb_10) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)](#idc5fa716a67d404f960e08e66d495bbb_13)</u> | [3](#idc5fa716a67d404f960e08e66d495bbb_13) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Income](#idc5fa716a67d404f960e08e66d495bbb_16)</u> | [3](#idc5fa716a67d404f960e08e66d495bbb_16) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Consolidated Statements of Comprehensive Income](#idc5fa716a67d404f960e08e66d495bbb_19)</u> | [4](#idc5fa716a67d404f960e08e66d495bbb_19) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Consolidated Balance Sheets](#idc5fa716a67d404f960e08e66d495bbb_22)</u> | [5](#idc5fa716a67d404f960e08e66d495bbb_22) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Consolidated Statements of Shareholders' Equity](#idc5fa716a67d404f960e08e66d495bbb_25)</u> | [6](#idc5fa716a67d404f960e08e66d495bbb_25) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Cash Flows](#idc5fa716a67d404f960e08e66d495bbb_28)</u> | [7](#idc5fa716a67d404f960e08e66d495bbb_28) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Notes to Condensed Consolidated Financial Statements](#idc5fa716a67d404f960e08e66d495bbb_31)</u> | [8](#idc5fa716a67d404f960e08e66d495bbb_31) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](#idc5fa716a67d404f960e08e66d495bbb_88)</u> | [20](#idc5fa716a67d404f960e08e66d495bbb_88) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Overview](#idc5fa716a67d404f960e08e66d495bbb_88)</u> | [20](#idc5fa716a67d404f960e08e66d495bbb_88) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Critical Accounting Policies and Estimates](#idc5fa716a67d404f960e08e66d495bbb_91)</u> | [20](#idc5fa716a67d404f960e08e66d495bbb_91) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Results of Operations](#idc5fa716a67d404f960e08e66d495bbb_94)</u> | [21](#idc5fa716a67d404f960e08e66d495bbb_94) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Financial Condition](#idc5fa716a67d404f960e08e66d495bbb_97)</u> | [22](#idc5fa716a67d404f960e08e66d495bbb_97) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK](#idc5fa716a67d404f960e08e66d495bbb_106)</u> | [23](#idc5fa716a67d404f960e08e66d495bbb_106) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[ITEM 4. CONTROLS AND PROCEDURES](#idc5fa716a67d404f960e08e66d495bbb_109)</u> | [23](#idc5fa716a67d404f960e08e66d495bbb_109) |
| <u>[PART II – OTHER INFORMATION](#idc5fa716a67d404f960e08e66d495bbb_112)</u> | [24](#idc5fa716a67d404f960e08e66d495bbb_112) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[ITEM 1. LEGAL PROCEEDINGS](#idc5fa716a67d404f960e08e66d495bbb_115)</u> | [24](#idc5fa716a67d404f960e08e66d495bbb_115) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[ITEM 1A. RISK FACTORS](#idc5fa716a67d404f960e08e66d495bbb_118)</u> | [24](#idc5fa716a67d404f960e08e66d495bbb_118) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS](#idc5fa716a67d404f960e08e66d495bbb_121)</u> | [24](#idc5fa716a67d404f960e08e66d495bbb_121) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[ITEM 6. EXHIBITS](#idc5fa716a67d404f960e08e66d495bbb_124)</u> | [25](#idc5fa716a67d404f960e08e66d495bbb_124) |
| <u>[SIGNATURE](#idc5fa716a67d404f960e08e66d495bbb_127)</u> | [26](#idc5fa716a67d404f960e08e66d495bbb_127) |

---

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**

**Part I – FINANCIAL INFORMATION**

---

| | |
|:---|:---|
| **ITEM 1.** | **FINANCIAL STATEMENTS (UNAUDITED)** |

---

**Condensed Consolidated Statements of Income** 

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| *(In thousands, except for per share data)* | **January 31, 2023** | **January 31, 2022** |
| **Sales** | $**610477** | $609166 |
| Operating costs and expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of sales | **281610** | 269032 |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling and administrative expenses | **184648** | 184274 |
|  | **466258** | 453306 |
| **Operating profit** | **144219** | 155860 |
| Other income (expense): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | **(10530)** | (5650) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest and investment income | **587** | 465 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other - net | **(3196)** | 1292 |
|  | **(13139)** | (3893) |
| **Income before income taxes** | **131080** | 151967 |
| Income taxes | **26819** | 31558 |
| **Net income** | $**104261** | $120409 |
| **Average common shares** | **57170** | 58152 |
| Incremental common shares attributable to equity compensation | **592** | 667 |
| **Average common shares and common share equivalents** | **57762** | 58819 |
| **Basic earnings per share** | $**1.82** | $2.07 |
| **Diluted earnings per share** | $**1.81** | $2.05 |

---

See accompanying notes.

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

**Consolidated Statements of Comprehensive Income**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
| *(In thousands)* | **January 31, 2023** | **January 31, 2022** |
| Net income | $**104261** | $120409 |
| Components of other comprehensive income (loss): |  |  |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustments | **76821** | (13358) |
| &nbsp;&nbsp;&nbsp;Pension and other postretirement plan adjustments, net of tax | **(576)** | 3060 |
| Total other comprehensive income (loss) | **76245** | (10298) |
| Total comprehensive income | $**180506** | $110111 |

---

See accompanying notes.

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

**Consolidated Balance Sheets**

---

| | | |
|:---|:---|:---|
| *(In thousands)* |  |  |
| **Assets** |  |  |
| Current assets: | **January 31, 2023** | **October 31, 2022** |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $**121994** | $163457 |
| &nbsp;&nbsp;&nbsp;&nbsp;Receivables - net | **546649** | 537313 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories - net | **447727** | 383398 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | **62046** | 48803 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total current assets** | **1178416** | 1132971 |
| Goodwill | **2107113** | 1804693 |
| Intangible assets - net | **377835** | 329402 |
| Property, plant and equipment - net | **361447** | 353442 |
| Operating right of use lease assets | **111375** | 102279 |
| Deferred income taxes | **11994** | 10447 |
| Other assets | **89243** | 87141 |
| &nbsp;&nbsp;&nbsp;**Total assets** | $**4237423** | $3820375 |
| **Liabilities and shareholders' equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current maturities of long-term debt and notes payable | $**420947** | $392537 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | **156864** | 206828 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | **90602** | 99276 |
| &nbsp;&nbsp;&nbsp;&nbsp;Customer advanced payments | **97683** | 92584 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | **37161** | 22333 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liability - current | **17319** | 15738 |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance lease liability - current | **4885** | 4907 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total current liabilities** | **825461** | 834203 |
| Long-term debt | **595166** | 345320 |
| Operating lease liability - noncurrent | **97179** | 90768 |
| Deferred income taxes | **121152** | 110781 |
| Postretirement obligations | **56953** | 56804 |
| Pension obligations | **45114** | 40551 |
| Finance lease liability - noncurrent | **11070** | 11184 |
| Other long-term liabilities | **38643** | 36389 |
| Shareholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common shares | **12253** | 12253 |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital in excess of stated value | **640800** | 626697 |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | **3719278** | 3652216 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | **(131537)** | (207782) |
| &nbsp;&nbsp;&nbsp;&nbsp;Common shares in treasury, at cost | **(1794109)** | (1789009) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total shareholders' equity | **2446685** | 2294375 |
| &nbsp;&nbsp;&nbsp;**Total liabilities and shareholders' equity** | $**4237423** | $3820375 |

---

See accompanying notes.

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

**Consolidated Statements of Shareholders' Equity**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended January 31, 2023** | **Three Months Ended January 31, 2023** | **Three Months Ended January 31, 2023** | **Three Months Ended January 31, 2023** | **Three Months Ended January 31, 2023** | **Three Months Ended January 31, 2023** |
| *(In thousands, except for share and per share data)* | **Common<br>Shares** | **Additional<br>Paid-in<br>Capital** | **Retained<br>Earnings** | **Accumulated<br>Other<br>Comprehensive<br>Income (Loss)** | **Common<br>Shares in<br>Treasury,<br>at cost** | **TOTAL** |
| **November 1, 2022** | $**12253** | $**626697** | $**3652216** | $**(207782)** | $**(1789009)** | $**2294375** |
| Shares issued under company stock and employee benefit plans | **—** | 7032 | **—** | **—** | 1775 | **8807** |
| Stock-based compensation | **—** | 7071 | **—** | **—** | **—** | **7071** |
| Purchase of treasury shares | **—** | **—** | **—** | **—** | (6875) | **(6875)** |
| Dividends declared ($0.65 per share) | **—** | **—** | (37199) | **—** | **—** | **(37199)** |
| Net income | **—** | **—** | 104261 | **—** | **—** | **104261** |
| Other Comprehensive Income (Loss): |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign currency translation adjustments | **—** | **—** | **—** | 76821 | **—** | **76821** |
| &nbsp;&nbsp;Defined benefit pension and post-retirement<br>plan adjustments | **—** | **—** | **—** | (576) | **—** | **(576)** |
| **January 31, 2023** | $**12253** | $**640800** | $**3719278** | $**(131537)** | $**(1794109)** | $**2446685** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended January 31, 2022** | **Three Months Ended January 31, 2022** | **Three Months Ended January 31, 2022** | **Three Months Ended January 31, 2022** | **Three Months Ended January 31, 2022** | **Three Months Ended January 31, 2022** |
| *(In thousands, except for share and per share data)* | **Common<br>Shares** | **Additional<br>Paid-in<br>Capital** | **Retained<br>Earnings** | **Accumulated<br>Other<br>Comprehensive<br>Income (Loss)** | **Common<br>Shares in<br>Treasury,<br>at cost** | **TOTAL** |
| **November 1, 2021** | $**12253** | $**585334** | $**3265027** | $**(175835)** | $**(1527649)** | $**2159130** |
| Shares issued under company stock and employee benefit plans | **—** | 5046 | **—** | **—** | 675 | **5721** |
| Stock-based compensation | **—** | 8392 | **—** | **—** | **—** | **8392** |
| Purchase of treasury shares | **—** | **—** | **—** | **—** | (35002) | **(35002)** |
| Dividends declared ($0.51 per share) | **—** | **—** | (29724) | **—** | **—** | **(29724)** |
| Net income | **—** | **—** | 120409 | **—** | **—** | **120409** |
| Other Comprehensive Income (Loss): |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign currency translation adjustments | **—** | **—** | **—** | (13358) | **—** | **(13358)** |
| &nbsp;&nbsp;Defined benefit pension and post-retirement<br>plan adjustments | **—** | **—** | **—** | 3060 | **—** | **3060** |
| **January 31, 2022** | $**12253** | $**598772** | $**3355712** | $**(186133)** | $**(1561976)** | $**2218628** |

---

See accompanying notes.

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

**Condensed Consolidated Statements of Cash Flows**

---

| | | |
|:---|:---|:---|
| *(In thousands)* | **Three Months Ended** | **Three Months Ended** |
| **Cash flows from operating activities:** | **January 31, 2023** | **January 31, 2022** |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income | $**104261** | $120409 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | **26434** | 25390 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash stock compensation | **6239** | 8392 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | **(278)** | 1785 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other non-cash expense | **253** | 653 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on sale of property, plant and equipment | **10** | 193 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities | **(58371)** | (29217) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | **44789** | (9518) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | **123337** | 118087 |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions to property, plant and equipment | **(9302)** | (12491) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of property, plant and equipment | **9** | 7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition of business, net of cash acquired | **(377843)** | (171613) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | **(387136)** | (184097) |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from long-term debt | **566978** | 361 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayment of long-term debt | **(314700)** | (1618) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayment of finance lease obligations | **(1318)** | (1640) |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of common shares | **8807** | 5721 |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchase of treasury shares | **(6875)** | (35002) |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividends paid | **(37199)** | (29724) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) financing activities | **215693** | (61902) |
| **Effect of exchange rate changes on cash** | **6643** | (1521) |
| **Decrease in cash and cash equivalents** | **(41463)** | (129433) |
| **Cash and cash equivalents at beginning of period** | **163457** | 299972 |
| **Cash and cash equivalents at end of period** | $**121994** | $170539 |

---

See accompanying notes.

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

**Notes to Condensed Consolidated Financial Statements**

**January 31, 2023**

NOTE REGARDING AMOUNTS AND FISCAL YEAR REFERENCES

In this quarterly report, all amounts related to United States dollars and foreign currency and to the number of Nordson Corporation's common shares, except for per share earnings and dividend amounts, are expressed in thousands. Unless the context otherwise indicates, all references to "we" or the "Company" mean Nordson Corporation.

Unless otherwise noted, all references to years relate to our fiscal year ending October 31.

**Significant accounting policies**

<u>Basis of presentation</u>. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles in the United States (U.S. GAAP) for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended January 31, 2023 are not necessarily indicative of the results that may be expected for the full year. For further information, refer to the Consolidated Financial Statements and notes included in our Annual Report on Form 10-K for the year ended October 31, 2022.

<u>Consolidation</u>. The Condensed Consolidated Financial Statements include the accounts of Nordson Corporation and its 100%-owned and controlled subsidiaries. Investments in affiliates and joint ventures in which our ownership is 50% or less or in which we do not have control but have the ability to exercise significant influence, are accounted for under the equity method. All significant intercompany accounts and transactions have been eliminated in consolidation.

<u>Use of estimates</u>. The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements. Actual amounts could differ from these estimates.

<u>Revenue recognition</u>. A contract exists when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of the consideration is probable. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied. Generally, our revenue results from short-term, fixed-price contracts and primarily is recognized as of a point in time when the product is shipped or at a later point when the control of the product transfers to the customer. Revenue for undelivered items is deferred and included within Accrued liabilities in our Consolidated Balance Sheets. Revenues deferred as of January 31, 2023 and 2022 were not material.

However, for certain contracts related to the sale of customer-specific products within our Medical and Fluid Solutions segment, revenue is recognized over time as we satisfy performance obligations because of the continuous transfer of control to the customer. The continuous transfer of control to the customer occurs as we enhance assets that are customer controlled and we are contractually entitled to payment for work performed to date plus a reasonable margin.

As control transfers over time, revenue is recognized based on progress toward completion of the performance obligations. The selection method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. We have elected to use the input method – costs incurred for these contracts because it best depicts the transfer of products or services to the customer based on incurring costs on the contract. Under this method, revenues are recorded proportionally as costs are incurred. Contract assets recognized are recorded in Prepaid expenses and other current assets and contract liabilities are recorded in Accrued liabilities in our Consolidated Balance Sheets and were not material on January 31, 2023 and October 31, 2022. Revenue recognized over time represented approximately less than ten percent of our overall consolidated revenues at January 31, 2023 and October 31, 2022.

Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or services. Taxes, including sales and value add, that we collect concurrently with revenue-producing activities are excluded from revenue. As a practical expedient, we may exclude the assessment of whether goods or services are performance obligations, if they are immaterial in the context of the contract, and combine these with other performance obligations. While payment terms and conditions vary by contract type, we have determined that our contracts generally do not include a significant financing component. We have elected to apply the practical expedient to treat all shipping and handling costs as fulfillment costs as a significant portion of these costs are incurred prior to transfer of control to the customer. We have also elected to apply the practical expedient to expense sales commissions as they are incurred as the amortization period resulting from capitalizing the

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

costs is one year or less. These costs are recorded within Selling and administrative expenses in our Condensed Consolidated Statements of Income.

We offer assurance-type warranties on our products as well as separately sold warranty contracts. Revenue related to warranty contracts that are sold separately is recognized over the life of the warranty term and are not material. Certain arrangements may include installation, installation supervision, training, and spare parts, which tend to be completed in a short period of time, at an insignificant cost, and utilizing skills not unique to us, and, therefore, these items are typically regarded as inconsequential or not material.

We disclose disaggregated revenues by operating segment and geography in accordance with the revenue standard and on the same basis used internally by the chief operating decision maker for evaluating performance of operating segments and for allocating resources. Refer to our Operating segments Note for details.

<u>Earnings per share</u>. Basic earnings per share are computed based on the weighted-average number of common shares outstanding during each year, while diluted earnings per share are based on the weighted-average number of common shares and common share equivalents outstanding. Common share equivalents consist of shares issuable upon exercise of stock options computed using the treasury stock method, as well as restricted shares and deferred stock-based compensation. Options whose exercise price is higher than the average market price are excluded from the calculation of diluted earnings per share because the effect would be anti-dilutive. Options excluded from the calculation of diluted earnings per share for the three months ended January 31, 2023 and 2022 were 144 and 83, respectively.

**Recently issued accounting standards**

There have been no new accounting standards issued which would require either disclosure or adoption during the current period.

**Acquisitions**

Business acquisitions have been accounted for using the acquisition method, with the acquired assets and liabilities recorded at estimated fair value on the dates of acquisition. The cost in excess of the net assets of the business acquired is included in goodwill. Operating results since the respective dates of acquisitions are included in the Condensed Consolidated Statements of Income.

**2023 Acquisition**

On November 3, 2022 we acquired 100% of CyberOptics Corporation (CyberOptics). CyberOptics is a leading global developer and manufacturer of high-precision 3D optical sensing technology solutions. The CyberOptics acquisition expanded our test and inspection platform, providing differentiated technology that expands our product offering in the semiconductor and electronics industries and is reported in our Advanced Technology Solutions segment. We acquired CyberOptics for an aggregate purchase price of $377,843, net of cash of approximately $40,890, funded using borrowing under our revolving credit facility and cash on hand. Based on the fair value of the assets acquired and the liabilities assumed, goodwill of $279,630 and identifiable intangible assets of $58,600 were recorded. The identifiable intangible assets consist primarily of $15,200 of tradenames (amortized over fifteen years), $14,600 of technology (amortized over seven years), and $28,800 of customer contracts (amortized over twelve years). The results of CyberOptics are not material to our Consolidated Financial Statements. As of January 31, 2023, the purchase price allocation remains preliminary as we complete our assessment of intangibles and income taxes. The assets and liabilities acquired were as follows:

---

| | |
|:---|:---|
| | **November 3, 2022** |
| Cash | $40890 |
| Receivables - net | 21364 |
| Inventories - net | 35300 |
| Goodwill | 279630 |
| Intangibles | 58600 |
| Other assets | 14046 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Assets | $449830 |
| Accounts payable | $8109 |
| Deferred income taxes | 14294 |
| Other liabilities | 8694 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities | $31097 |

---

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

**2022 Acquisition**

On November 1, 2021, we acquired 100% of NDC Technologies (NDC), a leading global provider of precision measurement solutions for in-line manufacturing process control. NDC's technology portfolio includes in-line measurement sensors, gauges and analyzers using near-infrared, laser, X-ray, optical and nucleonic technologies, as well as proprietary algorithms and software. We acquired NDC for an aggregate purchase price of $171,613, net of cash of approximately $7,533 and other working capital adjustments of $2,763, utilizing cash on hand. Based on the fair value of the assets acquired and the liabilities assumed, goodwill of $131,129 and identifiable intangible assets of $31,130 were recorded. The identifiable intangible assets consist primarily of $10,800 of tradenames (amortized over thirteen years), $10,000 of technology (amortized over seven years), $9,500 of customer relationships (amortized over four years) and $830 of non-compete agreements (amortized over three years). Goodwill associated with this acquisition of $72,018 is tax deductible. This acquisition is being reported in our Industrial Precision Solutions segment and the results of NDC are not material to our Consolidated Financial Statements.

**Receivables**

Our allowance for credit losses is principally determined based on aging of receivables. Receivables are exposed to credit risk based on the customers' ability to pay which is influenced by, among other factors, their financial liquidity. We perform ongoing customer credit evaluation to maintain sufficient allowances for potential credit losses. Our segments perform credit evaluation and monitoring to estimate and manage credit risk through the review of customer information, credit ratings, approval and monitoring of customer credit limits, and assessment of market conditions. We may also require prepayments or bank guarantees from customers to mitigate credit risk. Our receivables are generally short-term in nature with a majority of receivables outstanding less than 90 days. Accounts receivable balances are written-off against the allowance if deemed uncollectible.

Accounts receivable are net of an allowance for credit losses of $9,148 and $8,218 on January 31, 2023 and October 31, 2022, respectively. The provision for losses on receivables was $348 and $471 for the three months ended January 31, 2023 and 2022, respectively. The remaining change in the allowance for credit losses is principally related to net write-off/recoveries of uncollectible accounts as well as currency translation.

**Inventories**

Components of inventories were as follows:

---

| | | |
|:---|:---|:---|
| | **January 31, 2023** | **October 31, 2022** |
| Finished goods | $**256243** | $218491 |
| Raw materials and component parts | **191185** | 157447 |
| Work-in-process | **57917** | 53195 |
|  | **505345** | 429133 |
| Obsolescence and other reserves | **(57618)** | (45735) |
|  | $**447727** | $383398 |

---

See Acquisitions Note for inventory increase attributable to acquisition of CyberOptics.

**Property, Plant and Equipment**

Components of property, plant and equipment were as follows:

---

| | | |
|:---|:---|:---|
| | **January 31, 2023** | **October 31, 2022** |
| Land | $**9780** | $9278 |
| Land improvements | **5029** | 4979 |
| Buildings | **284065** | 271450 |
| Machinery and equipment | **522574** | 505343 |
| Enterprise management system | **52564** | 52513 |
| Construction-in-progress | **28774** | 31466 |
| Leased property under finance leases | **28221** | 27512 |
|  | **931007** | 902541 |
| Accumulated depreciation and amortization | **(569560)** | (549099) |
|  | $**361447** | $353442 |

---

Depreciation expense was $12,562 and $12,305 for the three months ended January 31, 2023 and 2022, respectively.

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

**Goodwill and other intangible assets** 

Changes in the carrying amount of goodwill for the three months ended January 31, 2023 by operating segment were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Industrial<br>Precision<br>Solutions** | **Medical Fluid Systems** | **Advanced<br>Technology<br>Solutions** | **Total** |
| Balance at October 31, 2022 | $**520236** | $**1172069** | $**112388** | $**1804693** |
| Acquisitions | **—** | **—** | **279630** | **279630** |
| Currency effect | **15734** | **3751** | **3305** | **22790** |
| Balance at January 31, 2023 | $**535970** | $**1175820** | $**395323** | $**2107113** |

---

The increase in goodwill for the three months ended January 31, 2023 was due to the acquisition of CyberOptics. See Acquisitions Note for additional details.

Information regarding our intangible assets subject to amortization was as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **January 31, 2023** | **January 31, 2023** | **January 31, 2023** |
| | **Carrying <br>Amount** | **Accumulated<br>Amortization** | **Net Book <br>Value** |
| Customer relationships | $**516035** | $**264296** | $**251739** |
| Patent/technology costs | **175436** | **102181** | **73255** |
| Trade name | **99141** | **47151** | **51990** |
| Non-compete agreements | **10516** | **9665** | **851** |
| Other | **157** | **157** | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $**801285** | $**423450** | $**377835** |
|  | **October 31, 2022** | **October 31, 2022** | **October 31, 2022** |
|  | **Carrying <br>Amount** | **Accumulated<br>Amortization** | **Net Book <br>Value** |
| Customer relationships | $480058 | $250798 | $229260 |
| Patent/technology costs | 157549 | 96426 | 61123 |
| Trade name | 82759 | 44707 | 38052 |
| Non-compete agreements | 10253 | 9290 | 963 |
| Other | 446 | 442 | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $731065 | $401663 | $329402 |

---

Amortization expense for the three months ended January 31, 2023 and 2022 was $13,872 and $13,085, respectively. See Acquisitions Note for details regarding intangibles recorded due to the acquisition of CyberOptics.

**Pension and other postretirement plans**

The components of net periodic pension and other postretirement cost for the three months ended January 31, 2023 and 2022 were:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **U.S.** | **U.S.** | **International** | **International** |
| <u>Three Months Ended</u> | **2023** | **2022** | **2023** | **2022** |
| Service cost | $**2744** | $5187 | $**275** | $489 |
| Interest cost | **4175** | 3583 | **603** | 298 |
| Expected return on plan assets | **(6529)** | (7878) | **(377)** | (393) |
| Amortization of prior service cost (credit) | **—** | 12 | **(13)** | (18) |
| Amortization of net actuarial loss | **—** | 2766 | **20** | 607 |
| Total benefit cost | $**390** | $3670 | $**508** | $983 |

---

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

The components of other postretirement benefit costs for the three months ended January 31, 2023 and 2022 were:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **U.S.** | **U.S.** | **International** | **International** |
| <u>Three Months Ended</u> | **2023** | **2022** | **2023** | **2022** |
| Service cost | $**100** | $195 | $**1** | $3 |
| Interest cost | **765** | 488 | **3** | 3 |
| Amortization of net actuarial (gain) loss | **—** | 263 | **(16)** | (12) |
| Total benefit cost (income) | $**865** | $946 | $**(12)** | $(6) |

---

The components of net periodic pension and other postretirement cost other than service cost are included in Other – net in our Condensed Consolidated Statements of Income.

**Income taxes**

We record our interim provision for income taxes based on our estimated annual effective tax rate, as well as certain items discrete to the current period. The effective tax rate for the three months ended January 31, 2023 and 2022 was 20.5% and 20.8%, respectively.

Due to our share-based payment transactions, our income tax provision included a discrete tax benefit of $1,166 and $1,115, for the three months ended January 31, 2023 and 2022, respectively.

**Accumulated other comprehensive loss**

The components of accumulated other comprehensive income (loss), including adjustments for items that are reclassified from accumulated other comprehensive loss to net income, are shown below.

---

| | | | |
|:---|:---|:---|:---|
| | **Cumulative<br>translation<br>adjustments** | **Pension and<br>postretirement <br>benefit<br>plan adjustments** | **Accumulated<br>other <br>comprehensive<br>income (loss)** |
| Balance at October 31, 2022 | $**(160046)** | $**(47736)** | $**(207782)** |
| &nbsp;&nbsp;&nbsp;Pension and other postretirement plan adjustments, net of tax of ($195) | **—** | **(576)** | **(576)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustments | **76821** | **—** | **76821** |
| Balance at January 31, 2023 | $**(83225)** | $**(48312)** | $**(131537)** |

---

**Stock-based compensation**

During the 2021 Annual Meeting of Shareholders, our shareholders approved the Nordson Corporation 2021 Stock Incentive and Award Plan (the "2021 Plan") as the successor to the Amended and Restated 2012 Stock Incentive and Award Plan (the "2012 Plan"). The 2021 Plan provides for the granting of stock options, stock appreciation rights, restricted shares, restricted share units, performance shares, cash awards and other stock or performance-based incentives. A maximum of 900 common shares were authorized for grant under the 2021 Plan plus the number of shares that remained available to be granted under the 2012 Plan and additional shares registered related to the acquisition of CyberOptics. As of January 31, 2023, a total of 2,005 common shares were available to be granted under the 2021 Plan.

<u>Stock Options</u>

Nonqualified or incentive stock options may be granted to our employees and directors. Generally, options granted to employees may be exercised beginning one year from the date of grant at a rate not exceeding 25% per year and expire 10 years from the date of grant. Vesting accelerates upon a qualified termination in connection with a change in control. In the event of termination of employment due to early retirement or normal retirement at age 65, options granted within 12 months prior to termination are forfeited, and vesting continues post retirement for all other unvested options granted. In the event of disability or death, all unvested stock options granted within 12 months prior to termination fully vest. Termination for any other reason results in forfeiture of unvested options and vested options in certain circumstances. The amortized cost of options is accelerated if the retirement eligibility date occurs before the normal vesting date. Option exercises are satisfied through the issuance of treasury shares on a first-in, first-out basis. We recognized compensation expense related to stock options of $1,663 and $1,772 for the three months ended January 31, 2023 and 2022, respectively.

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

The following table summarizes activity related to stock options for the three months ended January 31, 2023:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Number of<br>Options** | **Weighted-<br>Average<br>Exercise Price <br>Per Share** | **Aggregate<br>Intrinsic Value** | **Weighted<br>Average<br>Remaining<br>Term** |
| Outstanding at October 31, 2022 | 1187 | $141.82 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Granted | 78 | 240.01 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Exercised | (73) | 122.96 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Forfeited or expired | (2) | 132.92 |  |  |
| Outstanding at January 31, 2023 | 1190 | $148.33 | $114851 | 5.4 years |
| Expected to vest | 257 | $213.45 | $9021 | 7.9 years |
| Exercisable at January 31, 2023 | 930 | $130.05 | $105762 | 4.7 years |

---

As of January 31, 2023, there was $10,669 of total unrecognized compensation cost related to unvested stock options. That cost is expected to be amortized over a weighted average period of approximately 1.9 years.

The fair value of each option grant was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

---

| | | | | |
|:---|:---|:---|:---|:---|
| <u>Three Months Ended</u> | **January 31, 2023** | **January 31, 2023** | **January 31, 2022** | **January 31, 2022** |
| Expected volatility | **30.4%** | **31.8%** | 30.6% | 30.8% |
| Expected dividend yield | **1.12%** | **1.12%** | 0.76% | 0.76% |
| Risk-free interest rate | **3.79%** | **3.82%** | 1.36% | 1.47% |
| Expected life of the option (in years) | **5.0** | **6.1** | 5.3 | 6.2 |

---

The weighted-average expected volatility used to value the 2023 and 2022 options was 30.6% and 30.6%, respectively.

Historical information was the primary basis for the selection of the expected volatility, expected dividend yield and the expected lives of the options. The risk-free interest rate was selected based upon yields of U.S. Treasury issues with a term equal to the expected life of the option being valued.

The weighted average grant date fair value of stock options granted during the three months ended January 31, 2023 and 2022 was $78.12 and $79.03, respectively.

The total intrinsic value of options exercised during the three months ended January 31, 2023 and 2022 was $8,350 and $6,961, respectively.

Cash received from the exercise of stock options for the three months ended January 31, 2023 and 2022 was $8,807 and $5,721, respectively.

<u>Restricted Shares and Restricted Share Units</u>

We may grant restricted shares and/or restricted share units to our employees and directors. These shares or units may not be transferred for a designated period of time (generally one to three years) defined at the date of grant. We may also grant continuation awards in the form of restricted share units with cliff vesting and a performance measure that must be achieved for the restricted share units to vest.

For employee recipients, in the event of termination of employment due to early retirement, with the consent of the Company, restricted shares and units granted within 12 months prior to termination are forfeited, and other restricted shares and units vest on a pro-rata basis, subject to the consent of the Compensation Committee. In the event of termination of employment due to normal retirement at age 65, restricted shares and units granted within 12 months prior to termination are forfeited, and, for other restricted shares and units, the restriction period applicable to restricted shares will lapse and the shares will vest and be transferable and all unvested units will become vested in full, subject to the consent of the Compensation Committee. In the event of a recipient's disability or death, all restricted shares and units granted within 12 months prior to termination fully vest. Termination for any other reason prior to the lapse of any restrictions or vesting of units results in forfeiture of the shares or units.

For non-employee directors, all restrictions lapse in the event of disability or death of the non-employee director. Termination of service as a director for any other reason within one year of date of grant results in a pro-rata vesting of shares or units.

As shares or units are issued, deferred stock-based compensation equivalent to the fair value on the date of grant is expensed over the vesting period.

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

The following table summarizes activity related to restricted shares during the three months ended January 31, 2023:

---

| | | |
|:---|:---|:---|
|  | **Number of Shares** | **Weighted-Average<br>Grant Date <br>Fair Value** |
| Restricted shares at October 31, 2022 | 6 | $167.99 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vested | (3) | 165.21 |
| Restricted shares at January 31, 2023 | 3 | $170.56 |

---

As of January 31, 2023, there was $173 of unrecognized compensation cost related to restricted shares. The cost is expected to be amortized over a weighted average period of 0.5 years. The amount charged to expense related to restricted shares during the three months ended January 31, 2023 and 2022 was $160 and $314, respectively, which included common share dividends of $2 and $5, respectively.

The following table summarizes activity related to restricted share units during the three months ended January 31, 2023:

---

| | | |
|:---|:---|:---|
|  | **Number of Units** | **Weighted-Average<br>Grant Date <br>Fair Value** |
| Restricted share units at October 31, 2022 | 81 | $223.77 |
| &nbsp;&nbsp;&nbsp;&nbsp;Granted | 36 | 237.68 |
| &nbsp;&nbsp;&nbsp;&nbsp;Forfeited | (2) | 242.02 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vested | (42) | 218.85 |
| Restricted share units at January 31, 2023 | 73 | $233.00 |

---

As of January 31, 2023, there was $14,661 of remaining expense to be recognized related to outstanding restricted share units, which is expected to be recognized over a weighted average period of 2.1 years. The amount charged to expense related to restricted share units during each of the three months ended January 31, 2023 and 2022 was $2,258 and $2,273.

<u>Performance Share Incentive Awards</u> 

Executive officers and selected other key employees are eligible to receive common share-based incentive awards. Payouts, in the form of unrestricted common shares, vary based on the degree to which corporate financial performance exceeds predetermined threshold, target and maximum performance goals over three-year performance periods. No payout will occur unless threshold performance is achieved.

The amount of compensation expense is based upon current performance projections and the percentage of the requisite service that has been rendered. The calculations are based upon the grant date fair value, which is principally driven by the stock price on the date of grant or a Monte Carlo valuation for awards with market conditions. The per share values were $231.34 in 2023, and $260.60, $273.50, and $221.94 for 2022. The amount charged to expense related to performance awards for the three months ended January 31, 2023 and 2022 was $2,062 and $3,944, respectively. The cumulative amount recorded in shareholders' equity at January 31, 2023 and 2022 was $10,603 and $10,959, respectively. As of January 31, 2023, there was $12,980 of unrecognized compensation cost related to performance share incentive awards.

<u>Deferred Compensation</u> 

Our executive officers and other highly compensated employees may elect to defer up to 100% of their base pay and cash incentive compensation, and for executive officers, up to 90% of their share-based performance incentive payout each year. Additional share units are credited for quarterly dividends paid on our common shares. Expense related to dividends paid under this plan for the three months ended January 31, 2023 and 2022 was $18 and $18, respectively.

<u>Deferred Directors' Compensation</u>

Non-employee directors may defer all or part of their cash and equity-based compensation until retirement. Cash compensation may be deferred as cash or as share equivalent units. Deferred cash amounts are recorded as liabilities, and share equivalent units are recorded as equity. Additional share equivalent units are earned when common share dividends are declared.

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

The following table summarizes activity related to director deferred compensation share equivalent units during the three months ended January 31, 2023:

---

| | | |
|:---|:---|:---|
|  | **Number of Shares** | **Weighted-Average<br>Grant Date Fair<br>Value** |
| Outstanding at October 31, 2022 | 90 | $77.70 |
| &nbsp;&nbsp;&nbsp;Distributions | (4) | 50.88 |
| Outstanding at January 31, 2023 | 86 | $79.73 |

---

The amount charged to expense related to director deferred compensation for the three months ended January 31, 2023 and 2022 was $80 and $76, respectively.

**Warranties**

We offer warranties to our customers depending on the specific product and terms of the customer purchase agreement. A typical warranty program requires that we repair or replace defective products within a specified time period (generally one year) from the date of delivery or first use. We record an estimate for future warranty-related costs based on actual historical return rates. Based on analysis of return rates and other factors, the adequacy of our warranty provisions are adjusted as necessary. The liability for warranty costs is included in Accrued liabilities in the Consolidated Balance Sheets.

Following is a reconciliation of the product warranty liability for the three months ended January 31, 2023 and 2022:

---

| | | |
|:---|:---|:---|
|  | **January 31, 2023** | **January 31, 2022** |
| Beginning balance at October 31 | $**11723** | $11113 |
| &nbsp;&nbsp;&nbsp;Accruals for warranties | **4809** | 3865 |
| &nbsp;&nbsp;&nbsp;Warranty payments | **(3186)** | (3051) |
| &nbsp;&nbsp;&nbsp;Currency effect | **215** | (10) |
| Ending balance | $**13561** | $11917 |

---

**Operating segments**

We conduct business in three primary operating segments: Industrial Precision Solutions, Medical and Fluid Solutions, and Advanced Technology Solutions. The composition of segments and measure of segment profitability is consistent with that used by our chief operating decision maker. The primary measure used by the chief operating decision maker for purposes of making decisions about allocating resources to the segments and assessing performance is operating profit, which equals sales less cost of sales and certain operating expenses. Items below the operating profit line of the Condensed Consolidated Statements of Income (interest and investment income, interest expense and other income/expense) are excluded from the measure of segment profitability reviewed by our chief operating decision maker and are not presented by operating segment. The accounting policies of the segments are the same as those described in the Significant accounting policies Note.

**Industrial Precision Solutions:** This segment focuses on delivering proprietary dispensing and processing technology, both standard and highly customized equipment, to diverse end markets. Product lines commonly reduce material consumption, increase line efficiency through precision dispense and measurement and control, and enhance product brand and appearance. Components are used for dispensing adhesives, coatings, paint, finishes, sealants and other materials. This segment primarily serves the industrial, consumer durables and non-durables markets.

**Medical and Fluid Solutions:** This segment includes the Company's fluid management solutions for medical, high-tech industrial and other diverse end markets. Related plastic tubing, balloons, catheters, syringes, cartridges, tips and fluid connection components are used to dispense or control fluids within customers' medical devices or products, as well as production processes.

**Advanced Technology Solutions:** This segment focuses on products serving electronics end markets. Advanced Technology Solutions products integrate our proprietary product technologies found in progressive stages of an electronics customer's production processes, such as surface treatment, precisely controlled dispensing of material and test and inspection to ensure quality and reliability. Applications include, but are not limited to, semiconductors, printed circuit boards, electronic components and automotive electronics.

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

The following table presents information about our segments:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| <u>Three Months Ended</u> | **Industrial<br>Precision<br>Solutions** | **Medical and Fluid Solutions** | **Advanced<br>Technology<br>Solutions** | **Corporate** | **Total** |
| January 31, 2023 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net external sales | $**311546** | $**154287** | $**144644** | $**—** | $**610477** |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating profit (loss) | **102319** | **39384** | **16963** | **(14447)** | **144219** |
| January 31, 2022 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net external sales | $323933 | $158784 | $126449 | $— | $609166 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating profit (loss) | 102187 | 49093 | 27234 | (22654) | 155860 |

---

We had significant sales in the following geographic regions:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **January 31, 2023** | **January 31, 2022** |
| Americas | $**264878** | $239901 |
| Europe | **162939** | 155985 |
| Asia Pacific | **182660** | 213280 |
| Total net external sales | $**610477** | $609166 |

---

**Fair value measurements**

The inputs to the valuation techniques used to measure fair value are classified into the following categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

The following tables present the classification of our assets and liabilities measured at fair value on a recurring basis:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **January 31, 2023** | **Total** | **Level 1** | **Level 2** | **Level 3** |
| Assets: |  |  |  |  |
| Foreign currency forward contracts <sup>(a)</sup> | $**12851** | $**—** | $**12851** | $**—** |
| &nbsp;&nbsp;Total assets at fair value | $**12851** | $**—** | $**12851** | $**—** |
| Liabilities: |  |  |  |  |
| &nbsp;&nbsp;Deferred compensation plans <sup>(b)</sup> | $**11118** | $**—** | $**11118** | $**—** |
| &nbsp;&nbsp;Foreign currency forward contracts <sup>(a)</sup> | **3401** | **—** | **3401** | **—** |
| Total liabilities at fair value | $**14519** | $**—** | $**14519** | $**—** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **October 31, 2022** | **Total** | **Level 1** | **Level 2** | **Level 3** |
| Assets: |  |  |  |  |
| &nbsp;&nbsp;Foreign currency forward contracts <sup>(a)</sup> | $5035 | $— | $5035 | $— |
| Total assets at fair value | $5035 | $— | $5035 | $— |
| Liabilities: |  |  |  |  |
| &nbsp;&nbsp;Deferred compensation plans <sup>(b)</sup> | $9076 | $— | $9076 | $— |
| &nbsp;&nbsp;Foreign currency forward contracts <sup>(a)</sup> | 11724 |  | 11724 |  |
| Total liabilities at fair value | $20800 | $— | $20800 | $— |

---

&nbsp;&nbsp;&nbsp;&nbsp;<sup>(a)</sup>We enter into foreign currency forward contracts to reduce the risk of foreign currency exposures resulting from receivables, payables, intercompany receivables, intercompany payables and loans denominated in foreign currencies. Foreign exchange contracts are valued using market exchange rates. These foreign exchange contracts are not designated as hedges.

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

&nbsp;&nbsp;&nbsp;&nbsp;<sup>(b)</sup>Executive officers and other highly compensated employees may defer up to 100% of their salary and annual cash incentive compensation and for executive officers, up to 90% of their long-term incentive compensation, into various non-qualified deferred compensation plans. Deferrals can be allocated to various market performance measurement funds. Changes in the value of compensation deferred under these plans are recognized each period based on the fair value of the underlying measurement funds.

The carrying amounts and fair values of financial instruments, other than cash and cash equivalents, receivables, and accounts payable, are shown in the table below. The carrying values of cash and cash equivalents, receivables and accounts payable approximate fair value due to the short-term nature of these instruments.

---

| | | |
|:---|:---|:---|
| | **January 31, 2023** | **January 31, 2023** |
| | **Carrying Amount** | **Fair Value** |
| Long-term debt (including current portion) | $**1016113** | $**1003337** |

---

Long-term debt is valued by discounting future cash flows at currently available rates for borrowing arrangements with similar terms and conditions, which are considered to be Level 2 inputs under the fair value hierarchy. The carrying amount of long-term debt is shown net of unamortized debt issuance costs as disclosed in the Long-term Debt Note.

**Derivative financial instruments** 

We operate internationally and enter into intercompany transactions denominated in foreign currencies. Consequently, we are subject to market risk arising from exchange rate movements between the dates foreign currency transactions occur and the dates they are settled. We regularly use foreign currency forward contracts to reduce our risks related to most of these transactions. These contracts usually have maturities of 90 days or less and generally require us to exchange foreign currencies for U.S. dollars at maturity, at rates stated in the contracts. These contracts are not designated as hedging instruments under U.S. GAAP. Accordingly, the changes in the fair value of the foreign currency forward contracts are recognized in each accounting period in "Other – net" on the Condensed Consolidated Statements of Income together with the transaction gain or loss from the related balance sheet position.

For the three months ended January 31, 2023, we recognized a net gain of $16,139 on foreign currency forward contracts and a net loss of $20,710 from the change in fair value of balance sheet positions. For the three months ended January 31, 2022, we recognized a net loss of $3,598 on foreign currency forward contracts and a net gain of $3,962 from the change in fair value of balance sheet positions. The fair values of our foreign currency forward contract assets and liabilities are included in Receivable-net and Accrued liabilities, respectively, in our Consolidated Balance Sheets. The following table summarizes, by currency, the foreign currency forward contracts outstanding at January 31, 2023 and 2022:

---

| | | |
|:---|:---|:---|
| **January 31, 2023 contract amounts:** | **Notional Sell Amounts** | **Notional Buy Amounts** |
| Euro | $**93142** | $**398560** |
| British pound | **27965** | **112945** |
| Mexican Peso | **11658** | **31315** |
| Japanese yen | **11644** | **35772** |
| Hong Kong dollar | **4180** | **148653** |
| Australian dollar | **375** | **8821** |
| Singapore dollar | **245** | **18862** |
| Taiwan Dollar | **—** | **35047** |
| Others | **3395** | **65175** |
| Total | $**152604** | $**855150** |
| **January 31, 2022 contract amounts:** | **Notional Sell Amounts** | **Notional Buy Amounts** |
| Euro | $102132 | $338128 |
| British pound | 34657 | 70869 |
| Japanese yen | 12315 | 40384 |
| Singapore dollar | 1079 | 18214 |
| Australian dollar | 325 | 10026 |
| Hong Kong dollar |  | 49595 |
| Others | 15792 | 87704 |
| Total | $166300 | $614920 |

---

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

We are exposed to credit-related losses in the event of nonperformance by counterparties to financial instruments. These financial instruments include cash deposits and foreign currency forward contracts. We periodically monitor the credit ratings of these counterparties in order to minimize our exposure. Our customers represent a wide variety of industries and geographic regions. For the three months ended January 31, 2023 and 2022, there were no significant concentrations of credit risk.

**Long-term debt**

A summary of long-term debt is as follows:

---

| | | |
|:---|:---|:---|
| | **January 31, 2023** | **October 31, 2022** |
| Revolving credit agreement, due 2024 | $**250000** | $— |
| Senior notes, due 2023-2025 | **55500** | 55500 |
| Senior notes, due 2023-2027 | **71429** | 71429 |
| Senior notes, due 2023-2030 | **350000** | 350000 |
| Euro loan, due 2023 | **287851** | 261893 |
| Notes payable and other | **2453** |  |
|  | **1017233** | 738822 |
| Less current maturities and notes payable | **420947** | 392537 |
| Less unamortized debt issuance costs | **1120** | 965 |
| Long-term maturities | $**595166** | $345320 |

---

**Revolving credit agreement, due 2024** — In April 2019, we entered into a $850,000 unsecured multi-currency credit facility with a group of banks, which amended, restated and extended our then existing syndicated revolving credit agreement. This facility has a five-year term and includes a $75,000 subfacility for swing-line loans. It expires in April 2024. The weighted-average interest rate at January 31, 2023 was 5.07%.

**Senior notes, due 2023-2025** — These unsecured fixed-rate notes entered into in 2012 with a group of insurance companies had a remaining weighted-average life of 1.21 years. The weighted-average interest rate at January 31, 2023 was 3.10%.

**Senior notes, due 2023-2027** — These unsecured fixed-rate notes entered into in 2015 with a group of insurance companies had a remaining weighted-average life of 2.19 years. The weighted-average interest rate at January 31, 2023 was 3.10%.

**Senior notes, due 2023-2030** — These unsecured fixed-rate notes entered into in 2018 with a group of insurance companies had a remaining weighted-average life of 2.79 years. The weighted-average interest rate at January 31, 2023 was 3.90%.

**Euro loan, due 2023** — In March 2020, we amended, restated and extended the term of our existing euro term loan facility with Bank of America Merrill Lynch International Limited. The interest rate is variable based on the EURIBOR rate. The term loan agreement provides for the following term loans due in two tranches: €115,000 is due in March 2023 and an additional €150,000 that was drawn down in March 2020 is due in March 2023. The weighted average interest rate at January 31, 2023 was 2.12%.

**Term loan, due 2024** — In January 2023, we entered into a $200,000 unsecured term loan facility. This facility has a 1.25 year term and expires in April 2024. At January 31, 2023, we had no balance outstanding under this facility.

We were in compliance with all covenants at January 31, 2023 and the amount we could borrow would not have been limited by any debt covenants.

**Contingencies**

We are involved in pending or potential litigation regarding environmental, product liability, patent, contract, employee and other matters arising from the normal course of business. Including the environmental matters discussed below, after consultation with legal counsel, we do not believe that losses in excess of the amounts we have accrued would have a material adverse effect on our financial condition, quarterly or annual operating results or cash flows.

<u>Environmental</u>

We have voluntarily agreed with the City of New Richmond, Wisconsin and other potentially responsible parties to share costs associated with the remediation of the City of New Richmond municipal landfill (the "Site") and the construction of a potable water delivery system serving the impacted area down gradient of the Site. As of January 31, 2023 and October 31, 2022, our accrual for the ongoing operation, maintenance and monitoring obligation at the Site was $266 and $266, respectively. The liability for environmental remediation represents management's best estimate of the probable and reasonably estimable undiscounted costs related to known remediation obligations. The accuracy of our estimate of environmental liability is affected by several uncertainties such as additional requirements that may be identified in connection with remedial activities, the

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

complexity and evolution of environmental laws and regulations, and the identification of presently unknown remediation requirements. Consequently, our liability could be greater than our current estimate. However, we do not expect that the costs associated with remediation will have a material adverse effect on our financial condition or results of operations.

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

**ITEM 2.&nbsp;&nbsp;&nbsp;&nbsp;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*The following is management's discussion and analysis of certain significant factors affecting our financial condition and results of operations for the periods included in the accompanying condensed consolidated financial statements.*

**Overview**

Nordson Corporation is an innovative precision technology company that leverages a scalable growth framework to deliver top tier growth with leading margins and returns. The Company's direct sales model and applications expertise serves global customers through a wide variety of critical applications. Its diverse end market exposure includes consumer non-durable, medical, electronics and industrial end markets. Founded in 1954 and headquartered in Westlake, Ohio, the Company has approximately 7,200 employees with operations and support offices in over 35 countries.

**<u>COVID-19 Update</u>**

In December 2019, a novel strain of coronavirus (COVID-19) emerged and has since spread to other countries, including the United States. In March 2020, the World Health Organization declared COVID-19 as a pandemic (the COVID-19 pandemic). The COVID-19 pandemic, including multiple variants, has resulted in governments around the world implementing stringent measures to help control the spread of the virus, including quarantines, "shelter in place" and "stay at home" orders, travel restrictions, business interruptions and other measures.

Throughout the COVID-19 pandemic, we have supported, and continue to support, multiple "critical infrastructure" sectors by manufacturing materials and products needed for medical supply chains, packaging, transportation, energy, communications, and other critical infrastructure industries. We have benefited from our geographical and product diversification as the end markets we serve have remained resilient in response to the COVID-19 pandemic, and we continue to invest in the businesses, people, and strategies necessary to achieve our long-term priorities as we focus on driving profitable growth. We have continued to operate during the COVID-19 pandemic in all our production facilities, having taken the recommended public health measures to ensure worker and workplace safety. As a result, there have been unfavorable impacts on our manufacturing efficiencies. Additionally, we are taking steps to offset cost increases from COVID-19 pandemic-related supply chain disruptions.

We continue to actively monitor the rapidly evolving circumstances and impact of the COVID-19 pandemic, which has negatively disrupted, and may continue to negatively disrupt, our business and results of operations in the future. For example, in the first quarter of 2023, our revenue growth in Asia-Pacific was negatively impacted by labor shortages and business disruption from the spread of COVID-19. The full extent of the COVID-19 pandemic on our operations and the markets we serve remains highly uncertain and will depend largely on future developments related to the COVID-19 pandemic, including infection rates increasing or returning in various geographic areas, variations of COVID-19, the ultimate duration of the COVID-19 pandemic, actions by government authorities to contain the outbreak or treat its impact, such as reimposing previously lifted measures or putting in place additional restrictions, and the widespread distribution and acceptance of an effective vaccine, among other things. These developments are constantly evolving and cannot be accurately predicted.

**<u>CyberOptics Acquisition</u>**

On November 3, 2022, the Company completed the acquisition of CyberOptics Corporation ("CyberOptics") pursuant to the terms of the Agreement and Plan of Merger, dated as of August 7, 2022, by and among the Company, Meta Merger Company and CyberOptics. CyberOptics is a leading global developer and manufacturer of high-precision 3D optical sensing technology solutions. The CyberOptics acquisition expanded our test and inspection platform, providing differentiated technology that expands our product offering in the semiconductor and electronics industries and will be reported in our Advanced Technology Solutions segment. The all-cash transaction of approximately $378,000, net of cash acquired, was funded using borrowings under our revolving credit facility and cash on hand and is not expected to have a material impact on our Consolidated Financial Statements.

**Critical Accounting Policies and Estimates**

A comprehensive discussion of the Company's critical accounting policies and management estimates and significant accounting policies followed in the preparation of the financial statements is included in Item 7 of our Annual Report on Form 10-K for the year ended October 31, 2022 (the 2022 Form 10-K). There have been no significant changes in critical accounting policies, management estimates or accounting policies followed since the year ended October 31, 2022.

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

**Results of Operations**

**<u>Three months ended January 31, 2023</u>**

Worldwide sales for the three months ended January 31, 2023 were $610,477, an increase of 0.2% from sales of $609,166 for the comparable period of 2022. The increase consisted of a 1.4% increase in organic sales and a favorable 2.8% increase due to an acquisition, which was partially offset by an unfavorable effect from currency translation of 4.0%. The organic sales increase was driven by strong demand in Europe and the Americas region, partially offset by weakness in the Asia Pacific region, predominantly in China.

In the Americas region, sales were $264,878 for the three months ended January 31, 2023, an increase of 10.4% from 2022, consisting of an organic sales increase of 8.6% and an increase due to an acquisition of 2.1%, partially offset by unfavorable currency effects of 0.3%. In the Asia Pacific region, sales were $182,660, a decrease of 14.4% from 2022, consisting of an organic sales decrease of 13.3% and a 5.8% decrease due to unfavorable currency effects, partially offset by a 4.7% increase due to an acquisition. In Europe, sales were $162,939, an increase of 4.5% from 2022, consisting of an organic sales increase of 10.7% and a 1.3% increase due to an acquisition, partially offset by unfavorable currency effects of 7.5%.

Cost of sales for the three months ended January 31, 2023 were $281,610, up from $269,032 in the comparable period of 2022. Gross profit, expressed as a percentage of sales, decreased to 53.9% from 55.8% in the comparable period of 2022. The 1.9 percentage point decrease in gross margin was primarily driven by the impact of passing through inflationary cost increases and incremental inventory step-up amortization of $2,743.

Selling and administrative expenses for the three months ended January 31, 2023 were $184,648, up from $184,274 in the comparable period of 2022. The 0.2% increase was primarily driven by the first-year effect of an acquisition, partially offset by favorable currency translation effects and a reduction in variable expenses.

Operating profit decreased to $144,219 for the three months ended January 31, 2023, compared to $155,860 in the comparable period of 2022. Operating profit as a percentage of sales decreased to 23.6% for the three months ended January 31, 2023 compared to 25.6% in the comparable period of 2022. The 2.0 percentage point decline in operating margin was primarily driven by fees, severance and non-cash inventory charges associated with the CyberOptics acquisition, as well as unfavorable currency translation effects.

Interest expense for the three months ended January 31, 2023 was $10,530, compared to $5,650 in the comparable period of 2022. The increase was primarily due to higher average debt levels compared to the prior year period, as well as increases in interest rates. Other expense was $3,196 compared to other income of $1,292 in the comparable period of 2022. Included in 2023 other expense were pension and postretirement income of $1,369 and $4,571 of foreign currency losses. Included in 2022 other income were pension and postretirement income of $281 and $364 of foreign currency gains.

Net income for the three months ended January 31, 2023 was $104,261, or $1.81 per diluted share, compared to $120,409, or $2.05 per diluted share, in the same period of 2022. This represents a 13.4% decrease in net income, and a 11.7% decrease in diluted earnings per share. The decrease was driven by a combination of fees, severance, and non-cash inventory charges associated with the CyberOptics acquisition, increased interest expense, and foreign currency losses.

*Industrial Precision Solutions*

Sales of the Industrial Precision Solutions segment were $311,546 in the three months ended January 31, 2023, a decrease of 3.8% from sales in the comparable period of 2022 of $323,933. The decrease consisted of an organic sales increase of 1.2%, which was offset by unfavorable currency effects that decreased sales by 5.0%. The organic sales increase was driven primarily by steady demand across most product lines and regions, offset by softness in the Asia Pacific region due to labor shortages and business disruption from the spread of COVID-19, as well as the timing of the Chinese New Year.

Operating profit as a percentage of sales increased to 32.8% for the three months ended January 31, 2023 compared to 31.5% in the comparable period of 2022. The 1.3 percentage point improvement in operating margin was primarily due to favorable product mix.

*Medical and Fluid Solutions*

Sales of the Medical and Fluid Solutions segment were $154,287 in the three months ended January 31, 2023, a decrease of 2.8% from sales in the comparable period of 2022 of $158,784. The decrease consisted of an organic sales decrease of 0.8% and unfavorable currency effects that decreased sales by 2.0%. The organic sales decrease was driven by lower demand for the medical fluid components product lines and fluid solutions product lines in China, offset by strong demand for medical interventional solutions product lines.

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

Operating profit as a percentage of sales decreased to 25.5% for the three months ended January 31, 2023 compared to 30.9% in the comparable period of 2022. The 5.4 percentage point decline in operating margin was primarily due to meaningful sales mix changes within medical product lines and related factory inefficiencies due to reduced volumes.

*Advanced Technology Solutions*

Sales of the Advanced Technology Solutions segment were $144,644 in the three months ended January 31, 2023, an increase of 14.4% from sales in the comparable period of 2022 of $126,449. The increase was the result of organic sales increase of 4.6% and a 13.5% increase due to an acquisition, partially offset by an unfavorable currency effect of 3.7%. The organic sales increase was driven by test and inspection product lines.

Operating profit as a percentage of sales decreased to 11.7% for the three months ended January 31, 2023 compared to 21.5% in the comparable period of 2022. The 9.8 percentage point decline in operating margin was primarily due to fees, severance and non-cash inventory charges of $10,295 associated with the CyberOptics acquisition and unfavorable sales mix.

**<u>Income taxes</u>**

We record our interim provision for income taxes based on our estimated annual effective tax rate, as well as certain items discrete to the current period. Significant judgment is involved regarding the application of global income tax laws and regulations and when projecting the jurisdictional mix of income. We have considered several factors in determining the probability of realizing deferred income tax assets which include forecasted operating earnings, available tax planning strategies and the time period over which the temporary differences will reverse. We review our tax positions on a regular basis and adjust the balances as new information becomes available. The effective tax rate for the three months ended January 31, 2023 was 20.5%, compared to 20.8% for the three months ended January 31, 2022.

**<u>Foreign Currency Effects</u>**

In the aggregate, average exchange rates for 2023 used to translate international sales and operating results into U.S. dollars were generally unfavorable compared with average exchange rates existing during 2022. It is not possible to precisely measure the impact on operating results arising from foreign currency exchange rate changes, because of changes in selling prices, sales volume, product mix and cost structure in each country in which we operate. However, if transactions for the three months ended January 31, 2023 were translated at exchange rates in effect during the same period of 2022, we estimated that sales would have been approximately $24,800 higher while costs of sales and selling and administrative expenses would have been approximately $16,600 higher.

**Financial Condition**

**<u>Liquidity and Capital Resources</u>**

During the three months ended January 31, 2023, cash and cash equivalents decreased $41,463 as cash was used to fund the CyberOptics acquisition, partially offset by incremental borrowings and cash generated from operations in the period. Cash provided by operations during this period was $123,337 compared to $118,087 for the three months ended January 31, 2022. Changes in operating assets and liabilities decreased cash by $58,371 in the three months ended January 31, 2023, primarily driven by a decrease in accounts payable and accrued liabilities, compared to decreasing cash by $29,217 in the comparable period of 2022. Other improved year over year due primarily to cash inflows related to settlement of foreign exchange contracts.

Cash used in investing activities was $387,136 for the three months ended January 31, 2023, compared to $184,097 used in the comparable period of 2022. During the three months ended January 31, 2023, cash of $377,843 was used for the CyberOptics acquisition and cash of $9,302 was used for capital expenditures. During the three months ended January 31, 2022, cash of $171,613 was used for the NDC acquisition and $12,491 was used for capital expenditures. The decrease in capital expenditures related primarily to 2022 expenditures being higher as a result of capacity expansion in our medical fluid dispensing and components product lines.

Cash provided by financing activities was $215,693 for the three months ended January 31, 2023, compared to $61,902 cash used in the comparable period of 2022. In the three months ended January 31, 2023, cash of $37,199 was used for dividend payments and cash of $6,875 was used for the purchase of treasury shares, compared to $29,724 and $35,002, respectively, in the comparable period of 2022. The three months ended January 31, 2023 included net borrowings of long-term debt of $252,278, used primarily to fund the acquisition of CyberOptics, compared to net repayments of $1,257 during the three months ended January 31, 2022.

The following is a summary of significant changes in balance sheet captions from October 31, 2022 to January 31, 2023. Inventories-net increased by $64,329, primarily as a result of the CyberOptics acquisition. Goodwill and intangibles increased by $279,630 and $58,600, respectively, due to the CyberOptics acquisition. Accrued liabilities decreased by $49,964 due primarily to incentive compensation payments made in the three months ended January 31, 2023, and long-term debt increased principally as result of borrowing $250,000 under the revolving credit facility for the CyberOptics acquisition.

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

We believe the combination of present capital resources, cash from operations and unused financing sources, such as our credit facilities, which includes our revolving credit facility and new term loan entered in January 2023, are more than adequate to meet cash requirements for the next twelve months and for the foreseeable future thereafter. There are no significant restrictions limiting the transfer of funds from international subsidiaries to the parent Company. We were in compliance with all debt covenants as of January 31, 2023. Refer to our Long-term debt Note in the notes to our condensed consolidated financial statements for additional details regarding our debt outstanding.

**Safe Harbor Statements Under the Private Securities Litigation Reform Act of 1995**

This Form 10-Q, particularly "Management's Discussion and Analysis of Financial Condition and Results of Operations," contains forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such statements relate to, among other things, income, earnings, cash flows, changes in operations, operating improvements, businesses in which we operate and the United States and global economies. Statements in this quarterly report that are not historical are hereby identified as "forward-looking statements" and may be indicated by words or phrases such as "anticipates," "supports," "plans," "projects," "expects," "believes," "should," "would," "could," "hope," "forecast," "management is of the opinion," use of the future tense and similar words or phrases. These statements reflect management's current expectations and involve a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, U.S. and international economic conditions; financial and market conditions; currency exchange rates and devaluations; possible acquisitions including the Company's ability to complete and successfully integrate acquisitions, including the integration of CyberOptics; the Company's ability to successfully divest or dispose of businesses that are deemed not to fit with its strategic plan; the effects of changes in U.S. trade policy and trade agreements; the effects of changes in tax law; and the possible effects of events beyond our control, such as political unrest, including the conflict between Russia and Ukraine and tensions between the United States and China, acts of terror, natural disasters and pandemics, including the COVID-19 pandemic.

In light of these risks and uncertainties, actual events and results may vary significantly from those included in or contemplated or implied by such statements. Readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Factors that could cause actual results to differ materially from the expected results are discussed in Part I, Item 1A, Risk Factors in our 2022 Form 10-K.

**ITEM 3.&nbsp;&nbsp;&nbsp;&nbsp;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Information regarding our financial instruments that are sensitive to changes in interest rates and foreign currency exchange rates was disclosed under Part II, Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" in our 2022 Form 10-K. The information disclosed has not changed materially in the interim period since then.

**ITEM 4. CONTROLS AND PROCEDURES**

Our management with the participation of the principal executive officer (President and Chief Executive Officer) and principal financial officer (Executive Vice President, Chief Financial Officer) has reviewed and evaluated our disclosure controls and procedures (as defined in the Securities Exchange Act Rule 13a-15(e)) as of January 31, 2023. Based on that evaluation, our management, including the principal executive and financial officers, has concluded that our disclosure controls and procedures were effective as of January 31, 2023 in ensuring that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and is accumulated and communicated to management, including the principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

There were no changes in our internal control over financial reporting that occurred during the three months ended January 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

**Part II – OTHER INFORMATION**

**ITEM 1.&nbsp;&nbsp;&nbsp;&nbsp;LEGAL PROCEEDINGS**

See our Contingencies Note to the condensed consolidated financial statements for a discussion of our contingencies and legal matters.

**ITEM 1A.&nbsp;&nbsp;&nbsp;&nbsp;RISK FACTORS**

In addition to the other information set forth in this report, you should carefully consider the risk factors disclosed in "Item 1A. Risk Factors" of our 2022 Form 10-K. Many of the risks identified in the 2022 Form 10-K have been, and may be further, exacerbated by the impact of the COVID-19 pandemic and the actions taken by governmental entities, businesses, individuals and others in response to the pandemic.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

The following table summarizes common shares repurchased by the Company during the three months ended January 31, 2023:

---

| | | | | |
|:---|:---|:---|:---|:---|
| *(In whole shares)* | **Total Number**<br>**of Shares**<br>**Purchased** <sup>(1)</sup> | **Average<br>Price Paid<br>per Share** | **Total Number of**<br>**Shares Purchased**<br>**as Part of Publicly**<br>**Announced Plans**<br>**or Programs** <sup>(2)</sup> | **Maximum Value**<br>**of Shares that**<br>**May Yet Be Purchased**<br>**Under the Plans**<br>**or Programs** <sup>(2)</sup> |
| November 1, 2022 to November 30, 2022 | 14351 | $234.07 |  | $631782 |
| December 1, 2022 to December 31, 2022 | 1180 | $236.43 |  | $631782 |
| January 1, 2023 to January 31, 2023 | 331 | $237.94 |  | $631782 |
| Total | 15862 |  |  |  |

---

<sup>(1)</sup> Includes shares tendered for taxes related to stock option exercises and vesting of restricted stock.

<sup>(2)</sup> In December 2014, the board of directors authorized a $300,000 common share repurchase program. In August 2015, the board of directors authorized the repurchase of up to an additional $200,000 of the Company's common shares. In August 2018, the board of directors authorized the repurchase of an additional $500,000 of the Company's common shares. In September 2022, the board of directors authorized the repurchase of up to an additional $500,000 of the Company's common shares. Approximately $631,782 of the total $1,500,000 authorized remained available for share repurchases at January 31, 2023. Uses for repurchased shares include the funding of benefit programs including stock options and restricted stock. Shares purchased are treated as treasury shares until used for such purposes. The repurchase program will be funded using cash from operations and proceeds from borrowings under our credit facilities. The repurchase program does not have an expiration date.

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

---

| | |
|:---|:---|
| **ITEM 6.** | **EXHIBITS** |

---

---

| | |
|:---|:---|
| <u>[4.1](http://www.sec.gov/Archives/edgar/data/72331/000007233123000024/pnc_nordson-termloanagreem.htm)</u> | Term Loan Agreement, dated as of January 18, 2023, by and among Nordson Corporation and Nordson Engineering GmbH, as Borrowers, and the Lenders party thereto and PNC Bank, as Administrative Agent, and PNC Capital Markets LLC, as Sole Lead Arranger and Sole Bookrunner (incorporated herein by reference to Exhibit 4.1 to Registrant's Form 8-K dated January 23, 2023) |
| <u>[10.1](exhibit101.htm)</u> | Nordson Corporation 2021 Stock Incentive and Award Plan, Form of Notice of Stock Options Award |
| <u>[10.2](exhibit102.htm)</u> | Nordson Corporation 2021 Stock Incentive and Award Plan, Form of Notice of Restricted Share Units Award |
| <u>[10.3](exhibit103.htm)</u> | Nordson Corporation 2021 Stock Incentive and Award Plan, Form of Notice of Performance Share Units Award |
| <u>[31.1](ndsn-20230131xex311.htm)</u> | Certification pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 by the Chief Executive Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| <u>[31.2](ndsn-20230131xex312.htm)</u> | Certification pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 by the Chief Financial Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| <u>[32.1](ndsn-20230131xex321.htm)</u> | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith). |
| <u>[32.2](ndsn-20230131xex322.htm)</u> | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith). |
| 101 | The following financial information from Nordson Corporation's Quarterly Report on Form 10-Q for the three months ended January 31, 2023 formatted in inline Extensible Business Reporting Language (iXBRL): (i) the Condensed Consolidated Statements of Income for the three months ended January 31, 2023 and 2022, (ii) the Consolidated Statements of Comprehensive Income for the three months ended January 31, 2023 and 2022, (iii) the Consolidated Balance Sheets at January 31, 2023 and October 31, 2022, (iv) the Consolidated Statements of Shareholders' Equity for the three months ended January 31, 2023 and 2022, (v) the Condensed Consolidated Statements of Cash Flows for the three months ended January 31, 2023 and 2022, and (vi) the Notes to Condensed Consolidated Financial Statements. |
| 104 | The cover page from Nordson Corporation's Quarterly Report on Form 10-Q for the quarter ended January 31, 2023, formatted in inline Extensible Business Reporting Language (iXBRL) (included in Exhibit 101). |

---

------

**<u>[**Table of Contents**](#idc5fa716a67d404f960e08e66d495bbb_7)</u>**

**Nordson Corporation**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
| Date: February 23, 2023 | Nordson Corporation |
|  | By: /s/ Joseph P. Kelley |
|  | Joseph P. Kelley |
|  | Executive Vice President, Chief Financial Officer |
|  | (Principal Financial Officer) |

---

## Exhibit 10.1

Exhibit 10.1

**NOTICE OF STOCK OPTION AWARD**

**NORDSON CORPORATION**

**2021 STOCK INCENTIVE AND AWARD PLAN**

Grantee:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Date of Grant:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Number of Shares:&nbsp;&nbsp;&nbsp;&nbsp;

Exercise Price:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Vesting Date(s):&nbsp;&nbsp;&nbsp;&nbsp;First, second, third and fourth anniversaries of the Date of Grant

Expiration Date:&nbsp;&nbsp;&nbsp;&nbsp;The tenth anniversary of the Date of Grant

Form of Grant:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nonqualified stock option

**<u>TERMS OF GRANT</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Grant of Stock Option.</u> On the Date of Grant set forth above, Nordson Corporation, an Ohio Corporation (the "Company"), grants to you, the individual named as Grantee above, in accordance with the terms and conditions of the Nordson Corporation 2021 Stock Incentive and Award Plan (the "Plan") and this Notice of Stock Option Award (the "Notice"), the option to purchase the number Shares set forth above (the "Option"). Please note that you must accept the Award set forth in this Notice online in accordance with the procedures established by the Company and the Plan's third-party administrator or this Notice may be cancelled by the Company, in its sole discretion. The terms and conditions of the Plan and this Notice constitute a legal contract that will bind both Grantee and the Company as soon as Grantee accepts the Award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Vesting and Forfeiture of Option</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;The Option shall become vested and exercisable as to one-fourth of the Shares (subject to such rounding conventions as maintained by the Company from time to time) on each of the Vesting Dates set forth above (each, a "Vesting Date"), provided that Grantee shall have remained in the continuous employment of the Company or a Subsidiary ("Continuous Service") through the applicable Vesting Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding Section 2(a):

&nbsp;&nbsp;&nbsp;&nbsp;(i) Upon the occurrence of a Change in Control prior to a Vesting Date and during Grantee's Continuous Service, the vesting and exercisability of the Option will be governed by the applicable provisions of Section 21 of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;(ii) In the event of the termination of Grantee's Continuous Service prior to a Vesting Date as a result of Grantee's death or "Disability" (defined as a physical or mental impairment, due to accident or illness that renders Grantee incapable of performing the duties of Grantee's normal occupation, as determined by the Committee (or its delegate); provided that the Committee (or its delegate) may, in its discretion, require that the existence of Disability be verified by a physician approved by the Committee (or its delegate)), any outstanding unvested portion of the Option shall automatically become vested and exercisable in full and shall remain exercisable until midnight on the Expiration Date.

&nbsp;&nbsp;&nbsp;&nbsp;(iii) In the event of the termination of Grantee's Continuous Service at least 12 months after the Date of Grant as a result of Grantee's "Retirement" (defined as Grantee's voluntary

------

termination of employment at or after age 65 and with no less than 5 years of service as determined by the Company), any outstanding unvested portion of the Option shall continue to vest and become exercisable on the remaining originally scheduled Vesting Dates and shall remain exercisable until midnight on the Expiration Date.

&nbsp;&nbsp;&nbsp;&nbsp;(iv) In the event of the termination of Grantee's Continuous Service at least 12 months after the Date of Grant as a result of Grantee's "Early Retirement" (defined as Grantee's voluntary termination of employment no earlier than age 55 but before age 65 and with no less than 5 years of service as determined by the Company), any outstanding unvested portion of the Option shall continue to vest and become exercisable on the remaining originally scheduled Vesting Dates and shall remain exercisable until the earlier of (A) the fifth anniversary of the date of Early Retirement or (B) midnight on the Expiration Date.

&nbsp;&nbsp;&nbsp;&nbsp;(v) In the event of the termination of Grantee's Continuous Service by the Company or a Subsidiary as a result of Grantee's violation of the Company's Code of Ethics and Business Conduct, the Option, whether vested or not, will be forfeited automatically without further action or notice on Grantee's termination date.

&nbsp;&nbsp;&nbsp;&nbsp;(vi) In the event of the termination of Grantee's Continuous Service for any other reason prior to a Vesting Date, any unvested portion of the Option will be forfeited automatically without further action or notice on Grantee's termination date, and any vested portion of the Option remain exercisable until the earlier of (A) 90 days after Grantee's termination date, or (B) midnight on the Expiration Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;To the extent not previously vested pursuant to Section 2(a), the Option shall be forfeited automatically without further action or notice if Grantee's Continuous Service with the Company or a Subsidiary terminates prior to a Vesting Date for any reason other than as provided pursuant to Section 2(b).

&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;The Option and any Shares acquired pursuant to this Notice are subject to forfeiture or repayment pursuant the Company's Clawback Policy (or any successor compensation recovery policy), as in effect from time to time (the "Clawback Policy"), to the extent applicable.

&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;Further, the Option and any Shares acquired pursuant to this Notice are subject to forfeiture or repayment due to Harmful Activity in accordance with the provisions of this Section 3(e).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) If Grantee engages in any Harmful Activity (as defined below) prior to or within one year after termination of employment with the Company, then then (A) any portion of the Option held by Grantee that has vested, (B) any Profits (as defined below) realized by Grantee or any transferee of Grantee upon the exercise of the Option (as defined below), and (C) any Profits realized upon the sale of any vested Shares acquired pursuant to the Option, which Profits are realized on or after one year prior to the date of termination of employment with the Company shall inure to the Company. This restriction shall not apply in the event that Grantee's employment with the Company is terminated under the provisions of any employment agreement between the Company and Grantee that becomes operative upon a Change in Control of the Company. If any vested Option, Shares or any Profits inure to the benefit of the Company in accordance with the first sentence of this paragraph, Grantee shall immediately forfeit such vested Option and shall provide all such forfeited Shares and pay all such Profits to the Company within 30 days after first engaging in any Harmful Activity, and any portion of the Option that has not yet vested shall immediately be forfeited and canceled. The Determination as to whether Grantee engaged in Harmful Activity prior to or within one year after termination of employment with the Company shall be at the Committee's discretion and such determination shall be final and conclusive.

&nbsp;&nbsp;&nbsp;&nbsp;(ii) For purposes of Section 3(e), "Harmful Activity" shall be deemed to have occurred if Grantee:

&nbsp;&nbsp;&nbsp;&nbsp;(A) Uses, publishes, sells, trades, or otherwise discloses Non-Public Information (defined below) of the Company unless such prohibited activity was inadvertent, done in good faith and did not cause significant harm to the Company;

------

&nbsp;&nbsp;&nbsp;&nbsp;(B) After written notice from the Company, fails to return to the Company any document, data, or thing in Grantee's possession or to which Grantee has access that may involve Non-Public Information of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;(C) After notice from the Company, fails to assign to the Company all right, title, and interest in and to any confidential or non-confidential Intellectual Property (defined below) which Grantee created, in whole or in part, during employment with the Company, including, without limitation, copyrights, trademarks, service marks, and patents in or to (or associated with) such Intellectual Property;

&nbsp;&nbsp;&nbsp;&nbsp;(D) After notice from the Company, fails to agree to do any acts and sign any document reasonably requested by the Company to assign and convey all right, title, and interest in and to any confidential or non-confidential Intellectual Property which Grantee created, in whole or in part, during employment with the Company, including, without limitation, the signing of patent applications and assignments thereof;

&nbsp;&nbsp;&nbsp;&nbsp;(E) Upon Grantee's own behalf or upon behalf of any other person or entity that competes or plans to compete with the Company, solicits or entices for employment or hire any employee of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;(F) Upon Grantee's own behalf or upon behalf of any other person or entity that competes or plans to compete with the Company, calls upon, solicits, or does business with (other than business which does not compete with any business conducted by the Company) any customer of the Company that Grantee called upon, solicited, interacted with, or became acquainted with, or learned of through access to information (whether or not such information is or was non-public) while employed at the Company unless such prohibited activity was inadvertent, done in good faith, and did not involve a customer whom Grantee should have reasonably known was a customer of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;(G) Upon Grantee's own behalf or upon the behalf of any other person or entity that competes or plans to compete with the Company, engages in any business activity in competition with the Company in the same or a closely related activity that Grantee was engaged in for the Company during the one-year period prior to the termination of employment;

&nbsp;&nbsp;&nbsp;&nbsp;(H) Engages in behavior that violates any non-competition provision of an agreement between Grantee and the Company; or

&nbsp;&nbsp;&nbsp;&nbsp;(I) Engages in behavior that violates the Company's Code of Ethics and Business Conduct.

&nbsp;&nbsp;&nbsp;&nbsp;(iii) For purposes of Section 3(e), "Intellectual Property" means any invention, idea, product, method of doing business, market or business plan, process, program, software, formula, method, work of authorship, or other information, or thing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) For purposes of Section 3(e), "Non-Public Information" means, but is not limited to, trade secrets, confidential processes, programs, software, formulas, methods, business information or plans, financial information, and listings of names (e.g., key employees, customers, and suppliers) that are developed, owned, utilized, or maintained by an employer such as the Company, and that of its customers or suppliers, and that are not generally known by the public.

&nbsp;&nbsp;&nbsp;&nbsp;(v) For purposes of Section 3(e), "Profits" means the Fair Market Value on the date of Grantee's sale of any Shares that were delivered to Grantee pursuant to this Notice.

&nbsp;&nbsp;&nbsp;&nbsp;(vi) For purposes of Section 3(e), "Company" includes the Company and its Subsidiaries.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Exercise of Option and Delivery of Shares</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;To the extent that the Option becomes vested and exercisable, it may be exercised in whole or in part from time to time by written notice to the Company or its designee stating the number of Shares for which the Option is being exercised, the intended manner of payment to cover the Exercise Price per Share, taxes or any brokerage fees or commissions, and such other provisions as

------

may be required by the Company or its designee. The vested Option may be exercised prior to its Expiration Date (or such earlier date as the Option may expire in accordance with Section 2 or Section 4 hereof), during the lifetime of Grantee, only by Grantee, or in the event of his legal incapacity, by his guardian or legal representative acting on behalf of Grantee in a fiduciary capacity under state law and court supervision. If Grantee dies before the expiration of the Option, all or part of the Option may be exercised (prior to expiration) by the personal representative of Grantee or by any person who has acquired the Option directly from Grantee by will, bequest, or inheritance but only to the extent that the Option was vested and exercisable upon Grantee's death.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;If, on the Expiration Date, (or if the Expiration Date is not a business day, the next preceding day in which the applicable securities exchange is open), any portion of the Option is vested and exercisable and the Fair Market Value per Share on such date is greater than the Exercise Price per Share, then such vested and exercisable portion of the Option shall be automatically exercised on such date without any further action by the Grantee (or the person or persons to whom the Option is transferred pursuant to a permitted transfer under Section 5), with the Exercise Price being paid by such method as determined by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;The exercise price and taxes due as a consequence of the exercise of the Option are payable (i) in cash or by certified or cashier's check or other cash equivalent acceptable to the Company payable to the order of the Company, (ii) by surrender of vested Shares (including by attestation) owned by Grantee having an aggregate Fair Market Value at the time of exercise equal to the total exercise price, (iii) by a reduction in the number of Shares to be received upon exercise of the Option, or (iv) by a combination of the foregoing methods.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms and conditions contained herein, Shares shall be delivered to Grantee as soon as administratively practicable following the date that Grantee (i) exercises the Option in accordance with the procedures outlined above, (ii) makes full payment to the Company or its designee of the Exercise Price and (iii) makes arrangements satisfactory to the Company (or any Subsidiary, if applicable) for the payment of any required withholding taxes or brokerage fees/commissions related to the exercise of the Option. Grantee shall not possess any incidents of ownership (including, without limitation, dividend and voting rights) in the Shares until such Shares have been delivered to Grantee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Term of Option</u>. Grantee may exercise the Option, to the extent vested, only during the term of the Option, which commences on the Date of Grant and, except as otherwise provided pursuant to Section 21 of the Plan in connection with a Change in Control, expires at midnight on the Expiration Date, or if earlier:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;On the date provided pursuant to Section 2(b)(i) through (vi) hereof, as applicable;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;In the event of the involuntary termination of Grantee's Continuous Service by the Company or a Subsidiary (other than on account of Grantee's death, disability or violation of the Company's Code of Ethics and Business Conduct), on the earlier of (i) 90 days after the date of termination, and (ii) midnight on the Expiration Date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;In the event of the voluntary termination of Grantee's Continuous Service by Grantee for any reason other than Retirement or Early Retirement, on the earlier of (i) 90 days after the date of termination, and (ii) midnight on the Expiration Date; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;In the event of the involuntary termination of Grantee's Continuous Service by the Company or a Subsidiary due to a violation of the Company's Code of Ethics and Business Conduct, immediately upon the termination date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Transferability</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;The Option shall be transferable in accordance with this Section 5 and to the extent so transferred, may be exercised by the transferee; provided, however, that (i) the Option shall only be transferable to Family Members, trusts with third party trustees and for the sole benefit of Family Member beneficiaries, partnerships whose only partners are Family Members, and organizations exempt

------

from income tax under §501(c)(3) of the Code (provided, in this latter case, that all transferred Options must be vested); (ii) any such transfer must be without consideration (except when required by court order); (iii) once transferred, the Option may not be further transferred by the transferee, except (a) by will or the laws of descent and distribution or (b) for a transfer by a trust or a partnership to a trust beneficiary or a partner, respectively; and (iv) the Company receives a copy of the document deemed necessary by the Committee establishing the validity of the transfer and requiring the transferee to accept and comply with the terms and conditions of the Option, the Plan and any related Committee rules.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Section 5, "Family Members" shall include children, stepchildren, grandchildren, parents, stepparents, grandparents, spouses, siblings, mothers-in-law, fathers-in-law, sons-in-law, daughters-in-law, brothers-in-law, sisters-in-law, nieces, or nephews, including adoptive relationships.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;In the event the Option has been transferred, Grantee will be obligated to pay, on the date of exercise, all taxes associated with the exercise of the Option. If Grantee fails to so pay all taxes associated with the exercise, such taxes will be paid by reducing the number of Shares to be received upon exercise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Tax Withholding</u>. To the extent the Company or any Subsidiary is required to withhold any federal, state, local, foreign or other taxes in connection with the exercise of the Option, then the Company or Subsidiary (as applicable) shall retain a number of Shares otherwise deliverable hereunder with a value equal to the required withholding (based on the fair market value of the Shares on the applicable date); provided that in no event shall the value of the Shares retained exceed the amount of taxes required to be withheld based on the maximum statutory tax rates in the applicable taxing jurisdictions. Notwithstanding the foregoing, Grantee may elect, in accordance with procedures adopted by the Company from time to time, to either (a) pay or provide for payment of the required tax withholding, or (b) have the required tax withholding deducted from any amount of salary, bonus, incentive compensation or other amounts otherwise payable in cash to Grantee; provided that the Company may require the use of one or both of these methods in the event that the Company or any Subsidiary is required to withhold taxes at any time other than upon delivery of the Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;<u>Relation to Other Benefits</u>. Any economic or other benefit to Grantee under this Notice or the Plan shall not be taken into account in determining any benefits to which Grantee may be entitled under any profit-sharing, retirement or other benefit or compensation plan maintained by the Company or a Subsidiary.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. In the event that one or more of the provisions of this Notice shall be invalidated for any reason by a court of competent jurisdiction, any provision so invalidated shall be deemed to be separable from the other provisions hereof, and the remaining provisions hereof shall continue to be valid and fully enforceable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. <u>Entire Agreement; Relation to Plan</u>. This Notice is subject to the terms and conditions of the Plan. This Notice and the Plan contain the entire agreement and understanding of the parties with respect to the subject matter contained in this Notice, and supersede all prior written or oral communications, representations, and negotiations in respect thereto. In the event of any inconsistency between the provisions of this Notice and the Plan, the Plan shall govern. Capitalized terms used in this Notice without definition shall have the meanings assigned to them in the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustments</u>. The number and kind of Shares subject to the Option are subject to adjustment as provided in Section 16 of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance with Law</u>. The Company shall make reasonable efforts to comply with all applicable federal and state securities laws and listing requirements with respect to delivery of Shares pursuant to the Option; provided, however, notwithstanding any other provision of this Notice, the Company shall not be obligated to deliver any Shares pursuant to this Notice if the delivery or vesting thereof would result in a violation of any such law or listing requirement.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. Without limiting Section 5, the provisions of this Notice shall inure to the benefit of, and be binding upon, the permitted successors, administrators, heirs, legal representatives and assigns of Grantee, and the successors and assigns of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;<u>Data Privacy</u>. In order to administer the Plan, the Company may process personal data about Grantee. Such data includes, but is not limited to, the information provided in this Notice and any changes thereto, other appropriate personal and financial data about Grantee such as home address and business addresses and other contact information, and any other information that might be deemed appropriate by the Company to facilitate the administration of the Plan. Grantee hereby gives explicit consent to the Company to process any such personal data. Grantee also gives explicit consent to the Company to transfer any such personal data outside the country in which Grantee works or is employed, including, if Grantee is not a U.S. resident, to the United States, to transferees that shall include the Company and other persons who are designated by the Company to administer the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;<u>Electronic Delivery</u>. Grantee hereby consents and agrees to electronic delivery of any documents that the Company may elect to deliver (including, but not limited to, the Plan document, Plan Summary and Prospectus, grant or award notifications, account statements, annual and quarterly reports, and all other forms of communications) in connection with this and any other award made or offered under the Plan. Grantee has the right at any time to request that the Company deliver written copies of any and all materials referred to above at no charge. Grantee also hereby consents to any and all procedures the Company has established or may establish for an electronic signature system for delivery and acceptance of any such documents that the Company may elect to deliver and agrees that Grantee's electronic response or signature is the same as, and shall have the same force and effect as, Grantee's manual signature.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendment</u>. Subject to the terms of the Plan, the Committee may modify this Notice upon written notice to Grantee. Any amendment to the Plan shall be deemed to be an amendment to this Notice to the extent that the amendment is applicable hereto. Notwithstanding the foregoing, no amendment of the Plan or this Notice shall adversely affect Grantee's rights under this Notice without Grantee's consent unless the Committee determines, in good faith, that such amendment is required for the Notice to either be exempt from the application of, or comply with, the requirements of Section 409A of the Code, or as otherwise may be provided in the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Employment Contract</u>. Nothing contained in this Notice shall confer upon Grantee any right with respect to continuance of employment by the Company and its subsidiaries, nor limit or affect in any manner the right of the Company and its subsidiaries to terminate Grantee's employment or adjust Grantee's compensation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law</u>. The interpretation, performance, and enforcement of this Notice shall be governed by the laws of the State of Ohio, without giving effect to the principles of conflict of laws thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.&nbsp;&nbsp;&nbsp;&nbsp;<u>Terms for Awards to Grantees Outside the United States</u>. If Grantee is a foreign national, or is subject to Applicable Laws of one or more non-United States jurisdictions, then Grantee's Award may be subject to such terms and conditions different from those specified in this Notice, and set out in an appendix to this Notice, as may in the judgment of the Committee be necessary or desirable to foster and promote achievement of the purposes of the Plan.

## Exhibit 10.2

Exhibit 10.2

**NOTICE OF RESTRICTED SHARE UNIT AWARD**

**NORDSON CORPORATION**

**2021 STOCK INCENTIVE AND AWARD PLAN**

Grantee:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Date of Grant:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Number of Restricted Share Units:&nbsp;&nbsp;&nbsp;&nbsp;

Vesting Dates:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;First, second and third anniversaries of the Date of Grant

**<u>TERMS OF GRANT</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Grant of Restricted Share Units</u>. Nordson Corporation, an Ohio corporation (the "Company"), grants to you, the individual named as Grantee above, in accordance with the terms and conditions of the Nordson Corporation 2021 Stock Incentive and Award Plan (the "Plan") and this Notice of Restricted Share Unit Award (the "Notice"), the number of restricted share units set forth above (the "Restricted Share Units"), on the Date of Grant set forth above. Each Restricted Share Unit represents the contingent right to receive one Share, subject to the terms and conditions of this Notice and the Plan. Please note that you must accept the Award set forth in this Notice online in accordance with the procedures established by the Company and the Plan's third-party administrator or this Notice may be cancelled by the Company, in its sole discretion. The terms and conditions of the Plan and this Notice constitute a legal contract that will bind both Grantee and the Company as soon as Grantee accepts the Award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Vesting of Restricted Share Units</u>.

&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;One-third of the Restricted Share Units (subject to such rounding conventions as maintained by the Company from time to time) shall vest on each of the Vesting Dates set forth above (each, a "Vesting Date"), provided that Grantee shall have remained in the continuous employment of the Company or a Subsidiary ("Continuous Service") through the applicable Vesting Date.

&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding Section 2(a):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Upon the occurrence of a Change in Control prior to a Vesting Date and during Grantee's Continuous Service, the vesting of the Restricted Share Units will be governed by the applicable provisions of Section 21 of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;(ii) In the event of the termination of Grantee's Continuous Service as a result of Grantee's death or "Disability" (defined as a physical or mental impairment, due to accident or illness that renders Grantee incapable of performing the duties of Grantee's normal occupation, as determined by the Committee (or its delegate); provided that the Committee (or its delegate) may, in its discretion, require that the existence of Disability be verified by a physician approved by the Committee (or its delegate)), any unvested Restricted Share Units shall become vested in full on Grantee's termination date.

&nbsp;&nbsp;&nbsp;&nbsp;(iii) In the event of the termination of Grantee's Continuous Service at least 12 months after the Date of Grant as a result of Grantee's "Retirement" (defined as Grantee's voluntary termination of employment at or after age 65 and with no less than 5 years of service as determined by the Company), any unvested Restricted Share Units shall become vested in full on Grantee's termination date, subject to the consent of the Committee (or its delegate).

&nbsp;&nbsp;&nbsp;&nbsp;(iv) In the event of the termination of Grantee's Continuous Service at least 12 months after the Date of Grant as a result of Grantee's "Early Retirement" (defined as Grantee's voluntary termination of employment no earlier than age 55 but before age 65 and with no less than 5 years of service as determined by the Company), subject to the consent of the Committee (or its delegate),

------

Grantee shall vest in a pro-rated number of Restricted Share Units (rounded to the nearest whole number) equal to (A) the total number of Restricted Share Units, multiplied by (B) a fraction, the numerator of which is the number of full months that have elapsed since the Date of Grant and the denominator of which in the number of full months of the full restricted period; provided that the Committee may, in its discretion, waive the forfeiture of any or all remaining unvested Restricted Share Units.

&nbsp;&nbsp;&nbsp;&nbsp;(v) In the event of the termination of Grantee's Continuous Service by the Company or a Subsidiary as a result of Grantee's violation of the Company's Code of Ethics and Business Conduct, all outstanding unvested Restricted Share Units will be forfeited automatically without further action or notice on Grantee's termination date.

&nbsp;&nbsp;&nbsp;&nbsp;(vi) The Committee may, in its sole discretion, provide for the vesting of all or a portion of the Restricted Share Units in connection with the termination of Grantee's Continuous Service for any other reason prior to a Vesting Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;The Restricted Share Units and any Shares delivered pursuant to this Notice are subject to forfeiture or repayment pursuant the Company's Clawback Policy (or any successor compensation recovery policy), as in effect from time to time (the "Clawback Policy"), to the extent applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;Further, the Restricted Share Units and any Shares delivered pursuant to this Notice are subject to forfeiture or repayment due to Harmful Activity in accordance with the provisions of this Section 2(d).

&nbsp;&nbsp;&nbsp;&nbsp;(i) If Grantee engages in any Harmful Activity (as defined below) prior to or within one year after termination of employment with the Company, then (a) any vested Restricted Share Units, and (b) any Profits (as defined below) from the sale of any Shares that were delivered pursuant to this Notice, which Profits are realized on or after one year prior to the date of termination of Grantee's employment with the Company, shall inure to the Company. This restriction shall not apply in the event that Grantee's employment with the Company is terminated under the provisions of any employment agreement between the Company and Grantee that becomes operative upon a Change in Control of the Company. If any vested Restricted Share Units or any Profits inure to the benefit of the Company in accordance with the first sentence of this paragraph, Grantee shall immediately forfeit such vested Restricted Share Units and shall provide all such forfeited Shares and pay all such Profits to the Company within 30 days after first engaging in any Harmful Activity, and all Restricted Share Units that have not yet vested shall immediately be forfeited and canceled. The Determination as to whether Grantee engaged in Harmful Activity prior to or within one year after termination of employment with the Company shall be at the Committee's discretion and such determination shall be final and conclusive.

&nbsp;&nbsp;&nbsp;&nbsp;(ii) For purposes of Section 2(d), "Harmful Activity" shall be deemed to have occurred if Grantee:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) Uses, publishes, sells, trades or otherwise discloses Non-Public Information (defined below) of the Company unless such prohibited activity was inadvertent, done in good faith and did not cause significant harm to the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) After written notice from the Company, fails to return to the Company any document, data, or thing in Grantee's possession or to which Grantee has access that may involve Non-Public Information of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C) After notice from the Company, fails to assign to the Company all right, title, and interest in and to any confidential or non-confidential Intellectual Property (defined below) which Grantee created, in whole or in part, during employment with the Company, including, without limitation, copyrights, trademarks, service marks, and patents in or to (or associated with) such Intellectual Property;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D) After notice from the Company, fails to agree to do any acts and sign any document reasonably requested by the Company to assign and convey all right, title, and interest in and to any confidential or non-confidential Intellectual Property which Grantee created, in whole or in

------

part, during employment with the Company, including, without limitation, the signing of patent applications and assignments thereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E) Upon Grantee's own behalf or upon behalf of any other person or entity that competes or plans to compete with the Company, solicits or entices for employment or hire any employee of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F) Upon Grantee's own behalf or upon behalf of any other person or entity that competes or plans to compete with the Company, calls upon, solicits, or does business with (other than business which does not compete with any business conducted by the Company) any customer of the Company that Grantee called upon, solicited, interacted with, or became acquainted with, or learned of through access to information (whether or not such information is or was non-public) while employed at the Company unless such prohibited activity was inadvertent, done in good faith, and did not involve a customer whom Grantee should have reasonably known was a customer of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(G) Upon Grantee's own behalf or upon the behalf of any other person or entity that competes or plans to compete with the Company, engages in any business activity in competition with the Company in the same or a closely related activity that Grantee was engaged in for the Company during the one-year period prior to the termination of employment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(H) Engages in behavior that violates any non-competition provision of an agreement between Grantee and the Company; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(I) Engages in behavior that violates the Company's Code of Ethics and Business Conduct.

&nbsp;&nbsp;&nbsp;&nbsp;(iii) For purposes of Section 2(d), "Intellectual Property" means any invention, idea, product, method of doing business, market or business plan, process, program, software, formula, method, work of authorship, or other information, or thing.

&nbsp;&nbsp;&nbsp;&nbsp;(iv) For purposes of Section 2(d), "Non-Public Information" means, but is not limited to, trade secrets, confidential processes, programs, software, formulas, methods, business information or plans, financial information, and listings of names (e.g., key employees, customers, and suppliers) that are developed, owned, utilized, or maintained by an employer such as the Company, and that of its customers or suppliers, and that are not generally known by the public.

&nbsp;&nbsp;&nbsp;&nbsp;(v) For purposes of Section 2(d), "Profits" means the fair market value on the date of Grantee's sale of any Shares that were delivered to Grantee pursuant to this Notice.

&nbsp;&nbsp;&nbsp;&nbsp;(vi) For purposes of Section 2(d), "Company" includes the Company and its Subsidiaries.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Payment of Vested Restricted Share Units</u>. The Company will deliver to Grantee the Shares underlying any vested Restricted Share Units (and pay to Grantee in cash any vested dividend equivalent amounts pursuant to Section 4 below) within 30 days after the date that such Restricted Share Units become vested. Notwithstanding the foregoing, to the extent that Grantee's Restricted Share Units constitute a "deferral of compensation" payable upon Grantee's "separation from service" and Grantee is a "specified employee" (within the meaning of Section 409A of the Code) at the time of such separation from service, payment of any vested Restricted Share Units shall be made, to the extent required by Section 409A of the Code, at least six months after Grantee's separation from service. Further, to the extent that Grantee's Restricted Share Units constitute a "deferral of compensation" within the meaning of Section 409A of the Code, payment of any vested Restricted Share Units pursuant to Section 21 of the Plan (relating to a Change in Control) shall be made within 60 days following the earlier of (i) the occurrence of a "change in the ownership," a "change in the effective control," or a "change in the ownership of a substantial portion of the assets" of the Company within the meaning of Section 409A of the Code; or (ii) Grantee's "separation from service" within the meaning of Section 409A of the Code; provided that payment to a "specified employee" within the meaning of Section 409A of the Code shall be made, to the extent required by Section 409A of the Code, at least six months after Grantee's separation from service.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>No Dividend or Voting Rights; Dividend Equivalents</u>. Grantee shall have no rights of ownership in the Restricted Share Units or in the Shares related thereto and shall have no right to dividends and no right to vote the Restricted Share Units or the Shares related thereto until the date on which the Shares underlying the Restricted Share Units are delivered to Grantee. However, at each time from the Date of Grant through the applicable Vesting Date that the Company pays a cash dividend to shareholders, the Company shall credit Grantee's account hereunder with a dividend equivalent amount equal to the amount of such cash dividend per Share multiplied by the number of outstanding unvested Restricted Share Units on the dividend payment date. Any such dividend equivalent amount shall be accumulated and paid in cash (without interest) only at the time(s) and to the extent that the underlying Restricted Share Units become vested, subject to and conditioned upon Grantee's Continuous Service until such time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Non-Transferability</u>. The Restricted Share Units may not be sold, exchanged, assigned, transferred, pledged, encumbered or otherwise disposed of by Grantee, except by will or the laws of descent and distribution. Any purported transfer or encumbrance in violation of this provision shall be void, and the other party to any such purported transaction shall not obtain any rights to or interest in the Restricted Share Units.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Tax Withholding</u>. To the extent the Company or any Subsidiary is required to withhold any federal, state, local, foreign or other taxes in connection with the settlement of the Restricted Share Units, then the Company or Subsidiary (as applicable) shall retain a number of Shares otherwise deliverable hereunder with a value equal to the required withholding (based on the Fair Market Value of the Shares on the applicable date); provided that in no event shall the value of the Shares retained exceed the minimum amount of taxes required to be withheld or such other amount that will not result in a negative accounting impact. Notwithstanding the foregoing, Grantee may elect, in accordance with procedures adopted by the Company from time to time, to either (i) pay or provide for payment of the required tax withholding, or (ii) have the required tax withholding deducted from any amount of salary, bonus, incentive compensation or other amounts otherwise payable in cash to Grantee; provided that the Company may require the use of one or both of these methods in the event that the Company or any Subsidiary is required to withhold taxes at any time other than upon delivery of the Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;<u>Relation to Other Benefits</u>. Any economic or other benefit to Grantee under this Notice or the Plan shall not be taken into account in determining any benefits to which Grantee may be entitled under any profit-sharing, retirement or other benefit or compensation plan maintained by the Company or a Subsidiary.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. If one or more of the provisions of this Notice shall be invalidated for any reason by a court of competent jurisdiction, any provision so invalidated shall be deemed to be separable from the other provisions hereof, and the remaining provisions hereof shall continue to be valid and fully enforceable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;<u>Entire Agreement; Relation to Plan</u>. This Notice is subject to the terms and conditions of the Plan. This Notice and the Plan contain the entire agreement and understanding of the parties with respect to the subject matter contained in this Notice, and supersede all prior written or oral communications, representations and negotiations in respect thereto. In the event of any inconsistency between the provisions of this Notice and the Plan, the Plan shall govern. Capitalized terms used in this Notice without definition shall have the meanings assigned to them in the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustments</u>. The number and kind of the Restricted Share Units and the corresponding Shares are subject to adjustment as provided in Section 16 of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance with Law</u>. The Company shall make reasonable efforts to comply with all applicable federal and state securities laws and listing requirements with respect to the Shares underlying the Restricted Share Units; provided, however, notwithstanding any other provision of this Notice, the Company shall not be obligated to deliver any Shares pursuant to this Notice if the delivery thereof would result in a violation of any such law or listing requirement.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. Without limiting Section 5, the provisions of this Notice shall inure to the benefit of, and be binding upon, the permitted successors, administrators, heirs, legal representatives and assigns of Grantee, and the successors and assigns of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;<u>Data Privacy</u>. In order to administer the Plan, the Company may process personal data about Grantee. Such data includes, but is not limited to, the information provided in this Notice and any changes thereto, other appropriate personal and financial data about Grantee such as home address and business addresses and other contact information, and any other information that might be deemed appropriate by the Company to facilitate the administration of the Plan. Grantee hereby gives explicit consent to the Company to process any such personal data. Grantee also gives explicit consent to the Company to transfer any such personal data outside the country in which Grantee works or is employed, including, if Grantee is not a U.S. resident, to the United States, to transferees that shall include the Company and other persons who are designated by the Company to administer the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;<u>Electronic Delivery</u>. Grantee hereby consents and agrees to electronic delivery of any documents that the Company may elect to deliver (including, but not limited to, the Plan document, Plan Summary and Prospectus, grant or award notifications, account statements, annual and quarterly reports, and all other forms of communications) in connection with this and any other award made or offered under the Plan. Grantee has the right at any time to request that the Company deliver written copies of any and all materials referred to above at no charge. Grantee also hereby consents to any and all procedures the Company has established or may establish for an electronic signature system for delivery and acceptance of any such documents that the Company may elect to deliver and agrees that Grantee's electronic response or signature is the same as, and shall have the same force and effect as, Grantee's manual signature.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendment</u>. Subject to the terms of the Plan, the Committee may modify this Notice upon written notice to Grantee. Any amendment to the Plan shall be deemed to be an amendment to this Notice to the extent that the amendment is applicable hereto. Notwithstanding the foregoing, no amendment of the Plan or this Notice shall adversely affect Grantee's rights under this Notice without Grantee's consent unless the Committee determines, in good faith, that such amendment is required for the Notice to either be exempt from the application of, or comply with, the requirements of Section 409A of the Code, or as otherwise may be provided in the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Employment Contract</u>. Nothing contained in this Notice shall confer upon Grantee any right with respect to continuance of employment by the Company and its subsidiaries, nor limit or affect in any manner the right of the Company and its subsidiaries to terminate Grantee's employment or adjust Grantee's compensation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law</u>. The interpretation, performance, and enforcement of this Notice shall be governed by the laws of the State of Ohio, without giving effect to the principles of conflict of laws thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.&nbsp;&nbsp;&nbsp;&nbsp;<u>Terms for Awards to Grantees Outside the United States</u>. If Grantee is a foreign national, or is subject to Applicable Laws of one or more non-United States jurisdictions, then Grantee's Award may be subject to such terms and conditions different from those specified in this Notice, and set out in an appendix to this Notice, as may in the judgment of the Committee be necessary or desirable to foster and promote achievement of the purposes of the Plan.

## Exhibit 10.3

Exhibit 10.3

**NOTICE OF PERFORMANCE SHARE UNIT AWARD**

**NORDSON CORPORATION**

**2021 STOCK INCENTIVE AND AWARD PLAN**

Grantee:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Date of Grant:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Target Number of Performance Share Units:&nbsp;&nbsp;&nbsp;&nbsp;

Performance Period:&nbsp;&nbsp;&nbsp;&nbsp;Fiscal Year 2023 through Fiscal Year 2025

**<u>TERMS OF GRANT</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Grant of Performance Share Units</u>. Nordson Corporation, an Ohio corporation (the "Company"), grants to you, the individual named as Grantee above, in accordance with the terms and conditions of the Nordson Corporation 2021 Stock Incentive and Award Plan (the "Plan") and this Notice of Performance Share Unit Award (the "Notice"), the target number of performance share units set forth above (the "Performance Share Units"), on the Date of Grant set forth above. Each Performance Share Unit represents the contingent right to receive one Share, subject to the terms and conditions of this Notice and the Plan. Please note that you must accept the Award set forth in this Notice online in accordance with the procedures established by the Company and the Plan's third-party administrator or this Notice may be cancelled by the Company, in its sole discretion. The terms and conditions of the Plan and this Notice constitute a legal contract that will bind both Grantee and the Company as soon as Grantee accepts the Award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Performance Objectives; Determinations and Adjustments</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Grantee's right to receive a credit of all, a portion or a multiple of the target number of Performance Share Units shall be contingent upon the extent to which the Company achieves the Performance Objectives for the Performance Period, as determined in accordance with the performance schedule attached as <u>Exhibit A</u> to this Notice (the "Performance Schedule").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;After the end of the Performance Period, the Committee shall determine in writing the extent, if any, to which the Performance Objectives have been attained and shall determine, in accordance with the Performance Schedule, the number, if any, of Performance Share Units that have been earned, which shall be credited to a book entry account established for Grantee until payment in accordance with Section 4 hereof. Notwithstanding the foregoing, the Committee, in its sole discretion and without the consent of Grantee, may modify the Performance Objectives or the related threshold, target and maximum performance levels, or the actual payout, in whole or in part, as the Committee deems appropriate and equitable to reflect a change in the business, operations, corporate structure or capital structure of the Company or its affiliates, the manner in which it conducts its business or other events or circumstances.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Vesting and Forfeiture of Performance Share Units</u>.

&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;The Performance Share Units, if any, credited to Grantee's account pursuant to Section 2(b) hereof shall be fully vested, provided that Grantee shall have remained in the continuous employment of the Company or a Subsidiary ("Continuous Service") from the Date of Grant through the end of the Performance Period. Except as otherwise provided in Section 3(b) hereof, the Performance Share Units shall be forfeited automatically without further action or notice (i) in the event that the Performance Share Units are not earned based on the achievement of the Performance Objectives as determined by the Committee, or (ii) in the event of the termination of Grantee's Continuous Service for any reason prior to the end of the Performance Period.

&nbsp;&nbsp;&nbsp;&nbsp;

------

&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding Section 3(a):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Upon the occurrence of a Change in Control prior to the end of the Performance Period and during Grantee's Continuous Service, the vesting of the Performance Share Units will be governed by the applicable provisions of Section 21 of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;(ii) In the event of the termination of Grantee's Continuous Service as a result of Grantee's (A) "Disability" (defined as a physical or mental impairment, due to accident or illness that renders Grantee incapable of performing the duties of Grantee's normal occupation, as determined by the Committee (or its delegate); provided that the Committee (or its delegate) may, in its discretion, require that the existence of Disability be verified by a physician approved by the Committee (or its delegate)), (B) death, (C) "Retirement" (defined as Grantee's voluntary termination of employment at or after age 65 and with no less than 5 years of service as determined by the Company), or (D) "Early Retirement" (defined as Grantee's voluntary termination of employment no earlier than age 55 but before age 65 and with no less than 5 years of service as determined by the Company), Grantee shall vest in a pro-rated number of Performance Share Units (rounded to the nearest whole number) equal to (I) the number of Performance Share Units to which Grantee would have been entitled based on the actual performance of the Company during the full Performance Period, multiplied by (II) a fraction, the numerator of which is the number of days that Grantee was employed during the Performance Period and the denominator of which is the number of days in the Performance Period.

&nbsp;&nbsp;&nbsp;&nbsp;(iii) In the event of the termination of Grantee's Continuous Service by the Company or a Subsidiary as a result of Grantee's violation of the Company's Code of Ethics and Business Conduct, all outstanding vested and unvested Performance Share Units will be forfeited automatically without further action or notice on Grantee's termination date.

&nbsp;&nbsp;&nbsp;&nbsp;(iv) The Committee may, in its sole discretion, provide for the vesting of a pro-rated number of Performance Share Units (rounded to the nearest whole number and determined in accordance with the methodology set out in Section 3(b)(ii)) in connection with the termination of Grantee's Continuous Service for any other reason prior to the end of the Performance Period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;The Performance Share Units and any Shares delivered pursuant to this Notice are subject to forfeiture or repayment pursuant the Company's Clawback Policy (or any successor compensation recovery policy), as in effect from time to time (the "Clawback Policy"), to the extent applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;Further, the Performance Share Units and any Shares delivered pursuant to this Notice are subject to forfeiture or repayment due to Harmful Activity in accordance with the provisions of this Section 3(d).

&nbsp;&nbsp;&nbsp;&nbsp;(i) If Grantee engages in any Harmful Activity (as defined below) prior to or within one year after termination of employment with the Company, then (a) any vested Performance Share Units, and (b) any Profits (as defined below) from the sale of any Shares that were delivered pursuant to this Notice, which Profits are realized on or after one year prior to the date of termination of Grantee's employment with the Company, shall inure to the Company. This restriction shall not apply in the event that Grantee's employment with the Company is terminated under the provisions of any employment agreement between the Company and Grantee that becomes operative upon a Change in Control of the Company. If any vested Performance Share Units or any Profits inure to the benefit of the Company in accordance with the first sentence of this paragraph, Grantee shall immediately forfeit such vested Performance Share Units and shall provide all such forfeited Shares and pay all such Profits to the Company within 30 days after first engaging in any Harmful Activity, and all Performance Share Units that have not yet vested shall immediately be forfeited and canceled. The Determination as to whether Grantee engaged in Harmful Activity prior to or within one year after termination of employment with the Company shall be at the Committee's discretion and such determination shall be final and conclusive.

&nbsp;&nbsp;&nbsp;&nbsp;(ii) For purposes of Section 3(d), "Harmful Activity" shall be deemed to have occurred if Grantee:

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) Uses, publishes, sells, trades or otherwise discloses Non-Public Information (defined below) of the Company unless such prohibited activity was inadvertent, done in good faith and did not cause significant harm to the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) After written notice from the Company, fails to return to the Company any document, data, or thing in Grantee's possession or to which Grantee has access that may involve Non-Public Information of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C) After notice from the Company, fails to assign to the Company all right, title, and interest in and to any confidential or non-confidential Intellectual Property (defined below) which Grantee created, in whole or in part, during employment with the Company, including, without limitation, copyrights, trademarks, service marks, and patents in or to (or associated with) such Intellectual Property;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D) After notice from the Company, fails to agree to do any acts and sign any document reasonably requested by the Company to assign and convey all right, title, and interest in and to any confidential or non-confidential Intellectual Property which Grantee created, in whole or in part, during employment with the Company, including, without limitation, the signing of patent applications and assignments thereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E) Upon Grantee's own behalf or upon behalf of any other person or entity that competes or plans to compete with the Company, solicits or entices for employment or hire any employee of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F) Upon Grantee's own behalf or upon behalf of any other person or entity that competes or plans to compete with the Company, calls upon, solicits, or does business with (other than business which does not compete with any business conducted by the Company) any customer of the Company that Grantee called upon, solicited, interacted with, or became acquainted with, or learned of through access to information (whether or not such information is or was non-public) while employed at the Company unless such prohibited activity was inadvertent, done in good faith, and did not involve a customer whom Grantee should have reasonably known was a customer of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(G) Upon Grantee's own behalf or upon the behalf of any other person or entity that competes or plans to compete with the Company, engages in any business activity in competition with the Company in the same or a closely related activity that Grantee was engaged in for the Company during the one-year period prior to the termination of employment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(H) Engages in behavior that violates any non-competition provision of an agreement between Grantee and the Company; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(I) Engages in behavior that violates the Company's Code of Ethics and Business Conduct.

&nbsp;&nbsp;&nbsp;&nbsp;(iii) For purposes of Section 3(d), "Intellectual Property" means any invention, idea, product, method of doing business, market or business plan, process, program, software, formula, method, work of authorship, or other information, or thing.

&nbsp;&nbsp;&nbsp;&nbsp;(iv) For purposes of Section 3(d), "Non-Public Information" means, but is not limited to, trade secrets, confidential processes, programs, software, formulas, methods, business information or plans, financial information, and listings of names (e.g., key employees, customers, and suppliers) that are developed, owned, utilized, or maintained by an employer such as the Company, and that of its customers or suppliers, and that are not generally known by the public.

&nbsp;&nbsp;&nbsp;&nbsp;(v) For purposes of Section 3(d), "Profits" means the Fair Market Value on the date of Grantee's sale of any Shares that were delivered to Grantee pursuant to this Notice.

&nbsp;&nbsp;&nbsp;&nbsp;(vi) For purposes of Section 3(d), "Company" includes the Company and its Subsidiaries.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Payment of Vested Performance Share Units</u>. Payment of any Performance Share Units that become earned and vested in accordance with this Notice and the Plan will be made in the form of Shares no later than 90 days after the end of the Performance Period. Notwithstanding the foregoing, payment of any Performance Share Units that become vested pursuant to Section 21 of the Plan (relating to a Change in Control) generally shall be paid within 60 days after they become vested; provided that if the Performance Share Units are considered a "deferral of compensation" within the meaning of Section 409A of the Code, then, to the extent necessary to comply with Section 409A of the Code, any such vested Performance Share Units shall be paid within 60 days following the earlier of (i) the occurrence of a "change in the ownership," a "change in the effective control" or a "change in the ownership of a substantial portion of the assets" of the Company within the meaning of Section 409A of the Code; (ii) the end of the Performance Period; or (iii) Grantee's "separation from service" within the meaning of Section 409A of the Code (or the six-month anniversary of Grantee's separation from service, if Grantee is a "specified employee" within the meaning of Section 409A of the Code).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>No Dividend or Voting Rights</u>. Grantee shall have no rights of ownership in the Performance Share Units or in the Shares related thereto and shall have no right to dividends or dividend equivalents and no right to vote the Performance Share Units or the Shares related thereto until the date on which the Shares underlying the Performance Share Units are delivered to Grantee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Non-Transferability</u>. The Performance Share Units may not be sold, exchanged, assigned, transferred, pledged, encumbered or otherwise disposed of by Grantee, except by will or the laws of descent and distribution. Any purported transfer or encumbrance in violation of this provision shall be void, and the other party to any such purported transaction shall not obtain any rights to or interest in the Performance Share Units.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>Tax Withholding</u>. To the extent the Company or any Subsidiary is required to withhold any federal, state, local, foreign or other taxes in connection with the settlement of the Performance Share Units, then the Company or Subsidiary (as applicable) shall retain a number of Shares otherwise deliverable hereunder with a value equal to the required withholding (based on the fair market value of the Shares on the applicable date); provided that in no event shall the value of the Shares retained exceed the minimum amount of taxes required to be withheld or such other amount that will not result in a negative accounting impact. Notwithstanding the foregoing, Grantee may elect, in accordance with procedures adopted by the Company from time to time, to either (i) pay or provide for payment of the required tax withholding, or (ii) have the required tax withholding deducted from any amount of salary, bonus, incentive compensation or other amounts otherwise payable in cash to Grantee; provided that the Company may require the use of one or both of these methods in the event that the Company or any Subsidiary is required to withhold taxes at any time other than upon delivery of the Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;<u>Relation to Other Benefits</u>. Any economic or other benefit to Grantee under this Notice or the Plan shall not be taken into account in determining any benefits to which Grantee may be entitled under any profit-sharing, retirement or other benefit or compensation plan maintained by the Company or a Subsidiary.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. In the event that one or more of the provisions of this Notice shall be invalidated for any reason by a court of competent jurisdiction, any provision so invalidated shall be deemed to be separable from the other provisions hereof, and the remaining provisions hereof shall continue to be valid and fully enforceable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;&nbsp;&nbsp;&nbsp;<u>Entire Agreement; Relation to Plan</u>. This Notice is subject to the terms and conditions of the Plan. This Notice and the Plan contain the entire agreement and understanding of the parties with respect to the subject matter contained in this Notice, and supersede all prior written or oral communications, representations, and negotiations in respect thereto. In the event of any inconsistency between the provisions of this Notice and the Plan, the Plan shall govern. Capitalized terms used in this Notice without definition shall have the meanings assigned to them in the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustments</u>. The number and kind of the Performance Share Units and the corresponding Shares are subject to adjustment as provided in Section 16 of the Plan and in accordance with Company policies, including, but not limited to, those relating to foreign currency rates.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance with Law</u>. The Company shall make reasonable efforts to comply with all applicable federal and state securities laws and listing requirements with respect to the Shares underlying the Performance Share Units; provided, however, notwithstanding any other provision of this Notice, the Company shall not be obligated to deliver any Shares pursuant to this Notice if the delivery thereof would result in a violation of any such law or listing requirement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. Without limiting Section 6, the provisions of this Notice shall inure to the benefit of, and be binding upon, the permitted successors, administrators, heirs, legal representatives and assigns of Grantee, and the successors and assigns of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;<u>Data Privacy</u>. In order to administer the Plan, the Company may process personal data about Grantee. Such data includes, but is not limited to, the information provided in this Notice and any changes thereto, other appropriate personal and financial data about Grantee such as home address and business addresses and other contact information, and any other information that might be deemed appropriate by the Company to facilitate the administration of the Plan. Grantee hereby gives explicit consent to the Company to process any such personal data. Grantee also gives explicit consent to the Company to transfer any such personal data outside the country in which Grantee works or is employed, including, if Grantee is not a U.S. resident, to the United States, to transferees that shall include the Company and other persons who are designated by the Company to administer the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;<u>Electronic Delivery</u>. Grantee hereby consents and agrees to electronic delivery of any documents that the Company may elect to deliver (including, but not limited to, the Plan document, Plan Summary and Prospectus, grant or award notifications, account statements, annual and quarterly reports, and all other forms of communications) in connection with this and any other award made or offered under the Plan. Grantee has the right at any time to request that the Company deliver written copies of any and all materials referred to above at no charge. Grantee also hereby consents to any and all procedures the Company has established or may establish for an electronic signature system for delivery and acceptance of any such documents that the Company may elect to deliver and agrees that Grantee's electronic response or signature is the same as, and shall have the same force and effect as, Grantee's manual signature.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendment</u>. Subject to the terms of the Plan, the Committee may modify this Notice upon written notice to Grantee. Any amendment to the Plan shall be deemed to be an amendment to this Notice to the extent that the amendment is applicable hereto. Notwithstanding the foregoing, no amendment of the Plan or this Notice shall adversely affect Grantee's rights under this Notice without Grantee's consent unless the Committee determines, in good faith, that such amendment is required for the Notice to either be exempt from the application of, or comply with, the requirements of Section 409A of the Code, or as otherwise may be provided in the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Employment Contract</u>. Nothing contained in this Notice shall confer upon Grantee any right with respect to continuance of employment by the Company and its subsidiaries, nor limit or affect in any manner the right of the Company and its subsidiaries to terminate Grantee's employment or adjust Grantee's compensation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law</u>. The interpretation, performance, and enforcement of this Notice shall be governed by the laws of the State of Ohio, without giving effect to the principles of conflict of laws thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.&nbsp;&nbsp;&nbsp;&nbsp;<u>Terms for Awards to Grantees Outside the United States</u>. If Grantee is a foreign national, or is subject to Applicable Laws of one or more non-United States jurisdictions, then Grantee's Award may be subject to such terms and conditions different from those specified in this Notice, and set out in an appendix to this Notice, as may in the judgment of the Committee be necessary or desirable to foster and promote achievement of the purposes of the Plan.

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATIONS**

**CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Sundaram Nagarajan, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this quarterly report on Form 10-Q of Nordson Corporation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 23, 2023

---

| |
|:---|
| /s/ Sundaram Nagarajan |
| Sundaram Nagarajan |
| President and Chief Executive Officer |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Joseph P. Kelley, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this quarterly report on Form 10-Q of Nordson Corporation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 23, 2023

---

| |
|:---|
| /s/ Joseph P. Kelley |
| Joseph P. Kelley |
| Executive Vice President, Chief Financial Officer |

---

## Exhibit 32.1

**Exhibit 32.1**

**Certification**

**Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

**(Section 1350, Chapter 63 of Title 18, United States Code)**

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Section 1350, Chapter 63 of Title 18, United States Code), I, Sundaram Nagarajan, President and Chief Executive Officer of Nordson Corporation, an Ohio corporation (the "<u>Company</u>"), do hereby certify that, to the bet of my knowledge:

1. The Quarterly Report on Form 10-Q for the quarter ended January 31, 2023 of the Company (the "<u>Form 10-Q</u>") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. Information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Dated: February 23, 2023 | /s/ Sundaram Nagarajan |
| | Sundaram Nagarajan |
| | President and Chief Executive Officer |

---

## Exhibit 32.2

**Exhibit 32.2**

**Certification**

**Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

**(Section 1350, Chapter 63 of Title 18, United States Code)**

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Section 1350, Chapter 63 of Title 18, United States Code), I, Joseph P. Kelley, Executive Vice President, Chief Financial Officer of Nordson Corporation, an Ohio corporation (the "<u>Company</u>"), do hereby certify that, to the best of my knowledge:

1. The Quarterly Report on Form 10-Q for the quarter ended January 31, 2023 of the Company (the "<u>Form 10-Q</u>") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. Information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Dated: February 23, 2023 | /s/ Joseph P. Kelley |
| | Joseph P. Kelley |
| | Executive Vice President, Chief Financial Officer |

---

<br>